dan 2163 has been researched along with Dementia Praecox in 321 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In total, 327 inpatients with an acute exacerbation of schizophrenia were randomized to double-blind treatment with either olanzapine (5-20 mg/day) or amisulpride (200-800 mg/day)." | 9.51 | Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia. ( Bauer, M; Cordes, J; Davis, JM; Dehelean, L; Feyerabend, S; Fran, E; Hahn, E; Heres, S; Horowitz, M; Juckel, G; Ladea, M; Landgrebe, M; Lang, FU; Langguth, B; Lautenschlager, M; Leucht, S; Leweke, FM; Matei, V; Musil, R; Naber, D; Papava, I; Petcu C, C; Riedel, M; Ruhrmann, S; Schmidt-Kraepelin, C; Spellmann, I; Stefanescu, C; Ta, TMT; Tamasan, SC; van der List, T; Wolff-Menzler, C; Zamora, D, 2022) |
| "Although clozapine is an effective option for treatment-resistant schizophrenia (TRS), there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine." | 9.51 | Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. ( Hu, QY; Huang, Y; Jin, Y; Li, ZZ; Liu, MJ; Liu, ZJ; Lv, QY; Shi, DH; Tan, HY; Wu, FC; Yang, JY; Yi, ZH; Zhao, L; Zhu, MH; Zhu, N, 2022) |
| "Amisulpride was more efficacious than aripiprazole or olanzapine for reducing the PANSS total scores in adults with schizophrenia-spectrum disorders." | 9.34 | Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. ( Alisauskiene, R; Anda, LG; Bartz-Johannessen, C; Berle, JØ; Bjarke, J; Fathian, F; Fleischhacker, WW; Hugdahl, K; Joa, I; Johnsen, E; Kjelby, E; Kroken, RA; Larsen, TK; Løberg, EM; Reitan, SK; Rettenbacher, M; Sinkeviciute, I; Skrede, S; Stabell, L; Steen, VM; Walla, B, 2020) |
| "For most patients in the early stages of schizophrenia, symptomatic remission can be achieved using a simple treatment algorithm comprising the sequential administration of amisulpride and clozapine." | 9.27 | Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. ( Arango, C; Dazzan, P; Díaz-Caneja, CM; Drake, R; Eijkemans, MJC; Fleischhacker, WW; Galderisi, S; Glenthøj, B; Heres, S; Kahn, RS; Kapur, S; Leboyer, M; Leucht, S; Lewis, SW; McGuire, P; Rujescu, D; Sommer, IE; Weiser, M; Winter van Rossum, I, 2018) |
| "When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice." | 9.24 | Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. ( Amos, T; Bagalkote, H; Barnes, TR; Davies, L; Fitzgerald, Z; Fridrich, P; Haddad, PM; Husni, M; Iqbal, K; Keown, P; Kumar, R; Leeson, VC; Marston, L; Osborn, D; Paton, C; Singh, V; Whittaker, W; Zafar, R, 2017) |
| "Only limited data are available on the effectiveness of augmented antipsychotics to clozapine therapy in chronic schizophrenia." | 9.13 | Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. ( Assion, HJ; Basilowski, M; Juckel, G; Lemanski, S; Reinbold, H, 2008) |
| "The beneficial effect of sulpiride augmentation of clozapine therapy for treatment-resistant schizophrenia patients is enhanced by its antisalivatory effect on clozapine-induced hypersalivation (CIH)." | 9.12 | Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. ( Kreinin, A; Novitski, D; Weizman, A, 2006) |
| "We compared the efficacy of ziprasidone and amisulpride in the treatment of negative symptoms and overall psychopathology in subjects who had chronic schizophrenia with predominantly negative symptoms." | 9.12 | Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. ( Murray, S; Olié, JP; Spina, E; Yang, R, 2006) |
| "To compare the efficacy and safety of amisulpride and olanzapine in subjects with schizophrenia and comorbid depression in a randomised double-blind trial." | 9.12 | A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. ( Douki, S; Vanelle, JM, 2006) |
| " We have assessed the evolution of body weight and glycaemia during a 6-month randomized comparative trial of amisulpride and olanzapine." | 9.12 | Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. ( De Hert, M; Mortimer, A; Peuskens, J, 2007) |
| "Both amisulpride and olanzapine produce sustained improvement in certain measures of neuropsychological performance in patients with schizophrenia; a significant improvement in score on the AVLT was observed only with amisulpride." | 9.12 | Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. ( Balasubramaniam, K; Choudhary, PC; Joyce, E; Mortimer, AM; Saleem, PT, 2007) |
| "To determine the effectiveness of amisulpride on depression in patients with schizophrenia, in comparison to risperidone." | 9.12 | Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. ( Hwang, MY; Kim, JM; Kim, SW; Lee, JH; Lee, SH; Shin, IS; Yang, SJ; Yoon, BH; Yoon, JS, 2007) |
| "Treatment options are very limited for individuals with schizophrenia resistant to clozapine." | 9.11 | Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. ( Beer, MD; Cobb, AM; Kerwin, R; Launer, M; Matthiasson, P; Munro, J; Osborne, S; Purcell, S; Travis, M, 2004) |
| "To compare the efficacy and safety of the atypical antipsychotics amisulpride and olanzapine in the treatment of acute psychotic exacerbations of schizophrenia." | 9.10 | A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. ( Fleurot, O; Giudicelli, A; Lĵo, H; Martin, S; Peuskens, J; Rein, W; Thirumalai, S, 2002) |
| "This multicenter, double-blind, randomized study evaluated the efficacy, safety and functional effects of two atypical antipsychotics, amisulpride and risperidone, in patients with chronic schizophrenia (DSM IV) with a recent worsening of symptoms." | 9.10 | Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. ( Fleurot, O; Lecrubier, Y; Peuskens, J; Rein, W; Sechter, D, 2002) |
| "Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia." | 9.09 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999) |
| "In a multicentre, double-blind, flexible-dose study, 199 patients with paranoid schizophrenia or schizophreniform disorders received haloperidol (10-30 mg/d) or amisulpride (400-1200 mg/d) for four months." | 9.09 | Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). ( Bonhomme, D; Carrière, P; Lempérière, T, 2000) |
| " This study compared 800 mg/day amisulpride and 20 mg/day haloperidol in patients with acute exacerbations of schizophrenia." | 9.08 | Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. ( Boyer, P; Fleurot, O; Möller, HJ; Rein, W, 1997) |
| "The purpose of the present meta-analysis was to assess the efficacy of cannabidiol (CBD) oil in patients with schizophrenia." | 9.05 | The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis. ( Chourdakis, M; Goulas, A; Kopelli, E; Papazisis, G; Samara, M; Siargkas, A, 2020) |
| "Amisulpride was introduced into China in 2010 as a second-generation atypical antipsychotic, while olanzapine has been on the market since 1999 as one of the leading treatments for schizophrenia in China." | 8.98 | Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis. ( Li, C; Men, P; Qu, S; Xiong, T; Yi, Z; Yu, X; Zhai, S, 2018) |
| "Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels." | 8.95 | Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017) |
| "To measure the outcomes (both beneficial and harmful) of the clinical effectiveness, safety and cost-effectiveness of oral fluphenazine versus atypical antipsychotics for schizophrenia." | 8.93 | Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. ( Furtado, VA; Li, BG; Sampford, JR; Sampson, S; Xia, J; Zhao, S, 2016) |
| "To evaluate the effects of risperidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis." | 8.87 | Risperidone versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2011) |
| "We included all randomised trials that used at least single-blind (rater-blind) design, comparing oral olanzapine with oral forms of amisulpride, aripiprazole, clozapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis." | 8.86 | Olanzapine versus other atypical antipsychotics for schizophrenia. ( Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| "Although clozapine has been shown to be the treatment of choice in people with schizophrenia that are resistant to treatment, one third to two thirds of people still have persistent positive symptoms despite clozapine monotherapy of adequate dosage and duration." | 8.85 | Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. ( Barbui, C; Boso, M; Cipriani, A, 2009) |
| "We included all randomised, at least single-blind, controlled trials comparing oral ziprasidone with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone or zotepine in people with schizophrenia or schizophrenia-like psychoses." | 8.85 | Ziprasidone versus other atypical antipsychotics for schizophrenia. ( Bhoopathi, PS; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S, 2009) |
| "Risperidone and amisulpride caused hyperprolactinemia and macroprolactinemia; thus, detection of MPRL in the clinical setting should be performed as this phenomenon appears early in treatment (the second week) and continues, that can avoid unnecessary examination and treatment for asymptomatic patients with macroprolactinemia." | 8.12 | Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride. ( Haiying, J; Haizhi, C; Jianhua, L; Jianjun, L; Jing, L; Lilei, L; Xiaocong, F; Zhenhua, W, 2022) |
| "Both amisulpride and olanzapine are leading treatments for schizophrenia in China." | 7.96 | Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China. ( Li, C; Men, P; Qu, S; Yi, ZM; Yu, X; Zhai, S, 2020) |
| " Case description A 49-year-old man with schizophrenia, who was under maintenance treatment with olanzapine 20 mg/day, trihexyphenidyl 4 mg/day, and trazodone 50 mg/day, suffered from heat stroke in a heat wave and required intensive care." | 7.81 | Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia. ( Chang, CM; Chen, PJ; Lee, CP, 2015) |
| "The aim of the study was to investigate the prevalence rates of obsessive-compulsive disorder (OCD) and hypochondriasis in schizophrenic patients treated with atypical antipsychotics (AAPs) and to investigate the different comorbidity rates of OCD and hypochondriasis between clozapine-treated patients and patients treated with other AAPs." | 7.80 | Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. ( Cantisani, A; Ferrari, G; Grassi, G; Pallanti, S; Poli, L; Righi, L, 2014) |
| "Clozapine is used in the management of treatment-resistant schizophrenia and is effective in reducing aggression; however a subgroup of patients is poorly responsive." | 7.80 | Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. ( Basu, A; Brooman-White, RS; Das, M; Gupta, N; Hotham, JE; Humphreys, SA; Larkin, F; Ross, CC; Simpson, PJ, 2014) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 7.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "We compared stable patients with schizophrenia who were treated with either amisulpride or olanzapine in terms of symptomatic outcome, neurocognitive functioning, functionality, and subjective outcome." | 7.74 | Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. ( Bodner, T; Edlinger, M; Fleischhacker, WW; Hofer, A; Huber, R; Kemmler, G; Rettenbacher, MA; Sachs, G, 2007) |
| "Clozapine is the drug of choice for treatment-resistant schizophrenia." | 7.74 | Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives. ( Lang, UE; Malte Tugtekin, S; Matschke, K; Schmeisser, A; von Golitschek, R; Willbring, M, 2008) |
| "The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia." | 7.71 | Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002) |
| " Flexibly dosed monotherapy of oral amisulpride (amisulpride plus placebo, 200-800 mg per day) or olanzapine (olanzapine plus placebo, 5-20 mg per day) was compared with a combination of amisulpride plus olanzapine." | 7.11 | Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. ( Baumgärtner, J; Brockhaus-Dumke, A; Cordes, J; Correll, CU; Engelke, C; Englisch, S; Feyerabend, S; Gouzoulis-Mayfrank, E; Gründer, G; Hasan, A; Jäger, M; Kluge, M; Lange, C; Langguth, B; Leucht, S; Makiol, C; Meisenzahl-Lechner, E; Neff, A; Poeppl, TB; Reske, D; Riesbeck, M; Schmidt-Kraepelin, C; Verde, PE; Zink, M, 2022) |
| "Olanzapine has a related chemical structure and comparable receptor-binding profile as clozapine, which demonstrated superior efficacy in combination studies, but has a more unfavorable side-effect profile compared to olanzapine." | 6.94 | A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. ( Baumgärtner, J; Brockhaus-Dumke, A; Cordes, J; Correll, CU; Engelke, C; Englisch, S; Feyerabend, S; Gaebel, W; Gouzoulis-Mayfrank, E; Gründer, G; Hasan, A; Heres, S; Jäger, M; Kluge, M; Kolbe, H; Lange, C; Langguth, B; Leucht, S; Makiol, C; Meisenzahl-Lechner, E; Neff, A; Poeppl, T; Reske, D; Riesbeck, M; Schmidt-Kraepelin, C; Verde, PE; Wobrock, T; Zink, M, 2020) |
| "Tremor and insomnia were more frequent with amisulpride, while olanzapine caused more weight gain and sedation." | 6.75 | Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. ( Bhowmick, S; Ghosh, M; Hazra, A, 2010) |
| "This 4-week, double-blind, randomized study was undertaken to determine the dose-response relationship of amisulpride in 319 patients with acute exacerbation of schizophrenia." | 6.69 | Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. ( Fleurot, O; Puech, A; Rein, W, 1998) |
| "Schizophrenia is a chronic mental illness presented by cognitive deficits that precede its positive and negative symptoms." | 5.91 | Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. ( Abdelfattah, AM; Abuelezz, SA; Hendawy, N; Khalil, AMM; Nawishy, SAEK; Negm, EA, 2023) |
| "Relapse was determined by assessing changes in Positive and Negative Syndrome Scale (PANSS) total scores from baseline to 6 months (increased over 20% or 10% reaching 70)." | 5.91 | Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics. ( Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y, 2023) |
| "In total, 327 inpatients with an acute exacerbation of schizophrenia were randomized to double-blind treatment with either olanzapine (5-20 mg/day) or amisulpride (200-800 mg/day)." | 5.51 | Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia. ( Bauer, M; Cordes, J; Davis, JM; Dehelean, L; Feyerabend, S; Fran, E; Hahn, E; Heres, S; Horowitz, M; Juckel, G; Ladea, M; Landgrebe, M; Lang, FU; Langguth, B; Lautenschlager, M; Leucht, S; Leweke, FM; Matei, V; Musil, R; Naber, D; Papava, I; Petcu C, C; Riedel, M; Ruhrmann, S; Schmidt-Kraepelin, C; Spellmann, I; Stefanescu, C; Ta, TMT; Tamasan, SC; van der List, T; Wolff-Menzler, C; Zamora, D, 2022) |
| "Although clozapine is an effective option for treatment-resistant schizophrenia (TRS), there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine." | 5.51 | Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. ( Hu, QY; Huang, Y; Jin, Y; Li, ZZ; Liu, MJ; Liu, ZJ; Lv, QY; Shi, DH; Tan, HY; Wu, FC; Yang, JY; Yi, ZH; Zhao, L; Zhu, MH; Zhu, N, 2022) |
| "Aripiprazole is a first or second line treatment frequently used because it has reduced side effects such as weight gain, sleepiness, dyslipidemia, insulin resistance, hyperprolactinemia and extrapyramidal symptoms." | 5.43 | [Aripiprazole, gambling disorder and compulsive sexuality]. ( Dafreville, C; Mété, D; Paitel, V; Wind, P, 2016) |
| "Amisulpride was more efficacious than aripiprazole or olanzapine for reducing the PANSS total scores in adults with schizophrenia-spectrum disorders." | 5.34 | Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. ( Alisauskiene, R; Anda, LG; Bartz-Johannessen, C; Berle, JØ; Bjarke, J; Fathian, F; Fleischhacker, WW; Hugdahl, K; Joa, I; Johnsen, E; Kjelby, E; Kroken, RA; Larsen, TK; Løberg, EM; Reitan, SK; Rettenbacher, M; Sinkeviciute, I; Skrede, S; Stabell, L; Steen, VM; Walla, B, 2020) |
| "For most patients in the early stages of schizophrenia, symptomatic remission can be achieved using a simple treatment algorithm comprising the sequential administration of amisulpride and clozapine." | 5.27 | Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. ( Arango, C; Dazzan, P; Díaz-Caneja, CM; Drake, R; Eijkemans, MJC; Fleischhacker, WW; Galderisi, S; Glenthøj, B; Heres, S; Kahn, RS; Kapur, S; Leboyer, M; Leucht, S; Lewis, SW; McGuire, P; Rujescu, D; Sommer, IE; Weiser, M; Winter van Rossum, I, 2018) |
| "When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice." | 5.24 | Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. ( Amos, T; Bagalkote, H; Barnes, TR; Davies, L; Fitzgerald, Z; Fridrich, P; Haddad, PM; Husni, M; Iqbal, K; Keown, P; Kumar, R; Leeson, VC; Marston, L; Osborn, D; Paton, C; Singh, V; Whittaker, W; Zafar, R, 2017) |
| "Our results are consistent with those of a similar post-hoc analysis of hostility in first-episode subjects with schizophrenia enrolled in the European First-Episode Schizophrenia Trial (EUFEST) trial, where olanzapine demonstrated advantages compared with haloperidol, quetiapine, and amisulpride." | 5.19 | Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. ( Citrome, L; Czobor, P; Van Dorn, RA; Volavka, J, 2014) |
| " This study aimed to compare the efficacy and safety of low-dose amisulpride plus low-dose sulpiride with full-dose amisulpride in the treatment of acute schizophrenia." | 5.17 | Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study. ( Chen, CC; Huang, YH; Lane, HY; Lin, CH; Lin, SC; Wang, FC, 2013) |
| "The study was designed as a 6-week, two-center, fixed-dose, comparison study of 400 mg/day of amisulpride versus 300 mg/day of moclobemide as an adjunctive treatment in 53 schizophrenia and schizoaffective disorder patients (diagnosed according to DSM-IV) suffering from CIS." | 5.15 | Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation. ( Bergman, J; Kreinin, A; Lerner, V; Libov, I; Miodownik, C; Shestakova, D; Sokolik, S, 2011) |
| "To compare the effects of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on hostility in first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder." | 5.15 | Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). ( Bitter, I; Czobor, P; Derks, EM; Fleischhacker, WW; Kahn, RS; Libiger, J; Volavka, J, 2011) |
| "The primary objective of this randomised, active-controlled, parallel group, double-blind study was to evaluate the tolerability of treatment with either amisulpride or risperidone in elderly patients with schizophrenia aged over 65 years; evaluation of efficacy was a secondary objective." | 5.14 | A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. ( Eich, FX; Möller, HJ; Riedel, M, 2009) |
| "Only limited data are available on the effectiveness of augmented antipsychotics to clozapine therapy in chronic schizophrenia." | 5.13 | Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. ( Assion, HJ; Basilowski, M; Juckel, G; Lemanski, S; Reinbold, H, 2008) |
| "The beneficial effect of sulpiride augmentation of clozapine therapy for treatment-resistant schizophrenia patients is enhanced by its antisalivatory effect on clozapine-induced hypersalivation (CIH)." | 5.12 | Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. ( Kreinin, A; Novitski, D; Weizman, A, 2006) |
| "We compared the efficacy of ziprasidone and amisulpride in the treatment of negative symptoms and overall psychopathology in subjects who had chronic schizophrenia with predominantly negative symptoms." | 5.12 | Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. ( Murray, S; Olié, JP; Spina, E; Yang, R, 2006) |
| " We conducted a prospective, open study in schizophrenia patients in order to compare body weight and serum lipids during treatment with amisulpride, ziprasidone, clozapine or olanzapine over a period of 4 weeks." | 5.12 | Early changes of plasma lipids during treatment with atypical antipsychotics. ( Baumgartner, S; Ebenbichler, C; Edlinger, M; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Lechleitner, M; Rettenbacher, MA, 2006) |
| "To compare the efficacy and safety of amisulpride and olanzapine in subjects with schizophrenia and comorbid depression in a randomised double-blind trial." | 5.12 | A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. ( Douki, S; Vanelle, JM, 2006) |
| " We have assessed the evolution of body weight and glycaemia during a 6-month randomized comparative trial of amisulpride and olanzapine." | 5.12 | Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. ( De Hert, M; Mortimer, A; Peuskens, J, 2007) |
| "Both amisulpride and olanzapine produce sustained improvement in certain measures of neuropsychological performance in patients with schizophrenia; a significant improvement in score on the AVLT was observed only with amisulpride." | 5.12 | Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. ( Balasubramaniam, K; Choudhary, PC; Joyce, E; Mortimer, AM; Saleem, PT, 2007) |
| "To determine the effectiveness of amisulpride on depression in patients with schizophrenia, in comparison to risperidone." | 5.12 | Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. ( Hwang, MY; Kim, JM; Kim, SW; Lee, JH; Lee, SH; Shin, IS; Yang, SJ; Yoon, BH; Yoon, JS, 2007) |
| "Treatment options are very limited for individuals with schizophrenia resistant to clozapine." | 5.11 | Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. ( Beer, MD; Cobb, AM; Kerwin, R; Launer, M; Matthiasson, P; Munro, J; Osborne, S; Purcell, S; Travis, M, 2004) |
| "To compare the efficacy and safety of the atypical antipsychotics amisulpride and olanzapine in the treatment of acute psychotic exacerbations of schizophrenia." | 5.10 | A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. ( Fleurot, O; Giudicelli, A; Lĵo, H; Martin, S; Peuskens, J; Rein, W; Thirumalai, S, 2002) |
| "This multicenter, double-blind, randomized study evaluated the efficacy, safety and functional effects of two atypical antipsychotics, amisulpride and risperidone, in patients with chronic schizophrenia (DSM IV) with a recent worsening of symptoms." | 5.10 | Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. ( Fleurot, O; Lecrubier, Y; Peuskens, J; Rein, W; Sechter, D, 2002) |
| "This study suggests that amisulpride is as effective as risperidone in the treatment of patients with schizophrenia." | 5.10 | Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. ( Chen, YS; Hwang, TJ; Lee, SM; Lee, YC; Lin, HN; Sun, HJ; Tsai, SJ, 2003) |
| "Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia." | 5.09 | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999) |
| " In this long-term, open, randomised, multicentre trial, patients with chronic or subchronic schizophrenia received amisulpride (n =370) or haloperidol (n = 118) for 12 months." | 5.09 | Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. ( Colonna, L; Dondey-Nouvel, L; Rein, W; Saleem, P, 2000) |
| "In a multicentre, double-blind, flexible-dose study, 199 patients with paranoid schizophrenia or schizophreniform disorders received haloperidol (10-30 mg/d) or amisulpride (400-1200 mg/d) for four months." | 5.09 | Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). ( Bonhomme, D; Carrière, P; Lempérière, T, 2000) |
| " This study compared 800 mg/day amisulpride and 20 mg/day haloperidol in patients with acute exacerbations of schizophrenia." | 5.08 | Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. ( Boyer, P; Fleurot, O; Möller, HJ; Rein, W, 1997) |
| "The purpose of the present meta-analysis was to assess the efficacy of cannabidiol (CBD) oil in patients with schizophrenia." | 5.05 | The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis. ( Chourdakis, M; Goulas, A; Kopelli, E; Papazisis, G; Samara, M; Siargkas, A, 2020) |
| "Amisulpride was introduced into China in 2010 as a second-generation atypical antipsychotic, while olanzapine has been on the market since 1999 as one of the leading treatments for schizophrenia in China." | 4.98 | Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis. ( Li, C; Men, P; Qu, S; Xiong, T; Yi, Z; Yu, X; Zhai, S, 2018) |
| "Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels." | 4.95 | Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017) |
| "To measure the outcomes (both beneficial and harmful) of the clinical effectiveness, safety and cost-effectiveness of oral fluphenazine versus atypical antipsychotics for schizophrenia." | 4.93 | Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. ( Furtado, VA; Li, BG; Sampford, JR; Sampson, S; Xia, J; Zhao, S, 2016) |
| "To evaluate the effects of risperidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis." | 4.87 | Risperidone versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2011) |
| "We included randomised, at least single-blind, trials comparing oral amisulpride with oral forms of aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychoses." | 4.86 | Amisulpride versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S; Silveira da Mota Neto, JI, 2010) |
| "We included all randomised trials that used at least single-blind (rater-blind) design, comparing oral olanzapine with oral forms of amisulpride, aripiprazole, clozapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis." | 4.86 | Olanzapine versus other atypical antipsychotics for schizophrenia. ( Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| " Olanzapine produced more weight gain than all other second-generation antipsychotics except for clozapine where no difference was found." | 4.86 | Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. ( Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| "Although clozapine has been shown to be the treatment of choice in people with schizophrenia that are resistant to treatment, one third to two thirds of people still have persistent positive symptoms despite clozapine monotherapy of adequate dosage and duration." | 4.85 | Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. ( Barbui, C; Boso, M; Cipriani, A, 2009) |
| "We included all randomised, at least single-blind, controlled trials comparing oral ziprasidone with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone or zotepine in people with schizophrenia or schizophrenia-like psychoses." | 4.85 | Ziprasidone versus other atypical antipsychotics for schizophrenia. ( Bhoopathi, PS; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S, 2009) |
| "Risperidone and amisulpride caused hyperprolactinemia and macroprolactinemia; thus, detection of MPRL in the clinical setting should be performed as this phenomenon appears early in treatment (the second week) and continues, that can avoid unnecessary examination and treatment for asymptomatic patients with macroprolactinemia." | 4.12 | Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride. ( Haiying, J; Haizhi, C; Jianhua, L; Jianjun, L; Jing, L; Lilei, L; Xiaocong, F; Zhenhua, W, 2022) |
| "Both amisulpride and olanzapine are leading treatments for schizophrenia in China." | 3.96 | Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China. ( Li, C; Men, P; Qu, S; Yi, ZM; Yu, X; Zhai, S, 2020) |
| "Aminosulpiride is a benzamide used to treat acute or chronic schizophrenia Some researchers believe that early improvement of depression symptoms in patients has a certain predictive effect on the recovery of symptoms after drug treatment for schizophrenia." | 3.96 | Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study. ( Ni, Y; Pan, A; Wang, G; Zheng, L; Zhou, B, 2020) |
| "To investigate the clinical effects of aripiprazole on sexual dysfunction induced by amisulpride or risperidone in male patients with schizophrenia." | 3.85 | [Aripiprazole for drug-induced sexual dysfunction in schizophrenic males]. ( Gao, LJ; Guo, HG; Liang, ZT; Yang, Y; Zhong, XX; Zhu, JC, 2017) |
| "To investigate the role of SGA treatment on neural processing related to OCS in patients with schizophrenia, we stratified patients according to their monotherapy into 2 groups (group I: clozapine or olanzapine; group II: amisulpride or aripiprazole)." | 3.81 | Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia. ( Eifler, S; Englisch, S; Esslinger, C; Kirsch, P; Meyer-Lindenberg, A; Mier, D; Rausch, F; Schirmbeck, F; Zink, M, 2015) |
| "The addition of amisulpride could lead to an improvement in schizophrenia symptoms in patients that do not, or only partially, respond to risperidone." | 3.81 | Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy. ( Amorin-Díaz, M; Aparicio-Castro, E; López-Rodríguez, E; Molina, JD; Muñoz Algar, MJ; Toledo-Romero, F, 2015) |
| "Clozapine monotherapy is clearly the optimal medication in medication refractory schizophrenia and it is possible to maximise its use." | 3.81 | Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia. ( Joyce, DW; Mateos Fernandez, MJ; Sarkar, SN; Shergill, SS; Tracy, DK, 2015) |
| " Case description A 49-year-old man with schizophrenia, who was under maintenance treatment with olanzapine 20 mg/day, trihexyphenidyl 4 mg/day, and trazodone 50 mg/day, suffered from heat stroke in a heat wave and required intensive care." | 3.81 | Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia. ( Chang, CM; Chen, PJ; Lee, CP, 2015) |
| "The aim of the study was to investigate the prevalence rates of obsessive-compulsive disorder (OCD) and hypochondriasis in schizophrenic patients treated with atypical antipsychotics (AAPs) and to investigate the different comorbidity rates of OCD and hypochondriasis between clozapine-treated patients and patients treated with other AAPs." | 3.80 | Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. ( Cantisani, A; Ferrari, G; Grassi, G; Pallanti, S; Poli, L; Righi, L, 2014) |
| "Clozapine is used in the management of treatment-resistant schizophrenia and is effective in reducing aggression; however a subgroup of patients is poorly responsive." | 3.80 | Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. ( Basu, A; Brooman-White, RS; Das, M; Gupta, N; Hotham, JE; Humphreys, SA; Larkin, F; Ross, CC; Simpson, PJ, 2014) |
| "A 19-year-old man with schizophrenia and underlying cerebral disease developed rapid-onset mania after risperidone was replaced with amisulpride." | 3.80 | Amisulpride-associated mania in a young adult with schizophrenia and cerebral disease. ( Chen, CY; Chen, TY; Chuang, WC; Kuo, SC; Yeh, YW, 2014) |
| " Amisulpiride, a second generation antipsychotic drug is used in the treatment of schizophrenia and psychotic depression." | 3.79 | Safety of the electroconvulsive therapy and amisulpride combination. ( Gazdag, G; Iványi, Z; Takács, R; Ungvari, GS, 2013) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 3.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "Since oxidative stress observed in schizophrenia may be caused partially by the treatment of patients with various antipsychotics, the aim of the study was to establish the effects of beta-d-glucan, polysaccharide derived from the yeast cell walls of species such as Saccharomyces cerevisiae, and the antipsychotics (the first generation antipsychotic (FGA) - haloperidol and the second generation antipsychotic (SGA) - amisulpride) action on plasma lipid peroxidation in vitro." | 3.77 | Beta-glucan from Saccharomyces cerevisiae reduces plasma lipid peroxidation induced by haloperidol. ( Dietrich-Muszalska, A; Kontek, B; Olas, B; Rabe-Jabłońska, J, 2011) |
| "We stratified 70 patients with schizophrenia according to their mode of antipsychotic treatment: clozapine and olanzapine (group I) compared with aripiprazole and amisulpride (group II)." | 3.77 | Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. ( Englisch, S; Esslinger, C; Meyer-Lindenberg, A; Rausch, F; Schirmbeck, F; Zink, M, 2011) |
| " We conducted a prospective, open study comparing body weight, parameters of insulin resistance in schizophrenia patients treated with either clozapine (n = 10) or amisuLpride ( n = 12)." | 3.74 | Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. ( Baumgartner, S; Ebenbichler, C; Edlinger, M; Hofer, A; Hummer, M; Kemmler, G; Lechleitner, M; Rettenbacher, MA; Wolfgang Fleischhacker, W, 2007) |
| "We compared stable patients with schizophrenia who were treated with either amisulpride or olanzapine in terms of symptomatic outcome, neurocognitive functioning, functionality, and subjective outcome." | 3.74 | Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. ( Bodner, T; Edlinger, M; Fleischhacker, WW; Hofer, A; Huber, R; Kemmler, G; Rettenbacher, MA; Sachs, G, 2007) |
| " Patients aged 2 18 years who received an initial prescription for olanzapine, risperidone, quetiapine or amisulpride between April 1 and September 30, 2003; and had an ICD-10-coded diagnosis of schizophrenia were included." | 3.74 | Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis. ( Hui, HY; Law, WL; You, JH; Young, WM, 2007) |
| "Clozapine is the drug of choice for treatment-resistant schizophrenia." | 3.74 | Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives. ( Lang, UE; Malte Tugtekin, S; Matschke, K; Schmeisser, A; von Golitschek, R; Willbring, M, 2008) |
| "Clozapine had a significantly lower discontinuation rate in individuals with schizophrenia, compared to the other 4 SGAs." | 3.74 | Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. ( Lawrie, SM; Shajahan, P; Taylor, M, 2008) |
| "The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia." | 3.71 | Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002) |
| " Flexibly dosed monotherapy of oral amisulpride (amisulpride plus placebo, 200-800 mg per day) or olanzapine (olanzapine plus placebo, 5-20 mg per day) was compared with a combination of amisulpride plus olanzapine." | 3.11 | Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. ( Baumgärtner, J; Brockhaus-Dumke, A; Cordes, J; Correll, CU; Engelke, C; Englisch, S; Feyerabend, S; Gouzoulis-Mayfrank, E; Gründer, G; Hasan, A; Jäger, M; Kluge, M; Lange, C; Langguth, B; Leucht, S; Makiol, C; Meisenzahl-Lechner, E; Neff, A; Poeppl, TB; Reske, D; Riesbeck, M; Schmidt-Kraepelin, C; Verde, PE; Zink, M, 2022) |
| "Olanzapine has a related chemical structure and comparable receptor-binding profile as clozapine, which demonstrated superior efficacy in combination studies, but has a more unfavorable side-effect profile compared to olanzapine." | 2.94 | A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. ( Baumgärtner, J; Brockhaus-Dumke, A; Cordes, J; Correll, CU; Engelke, C; Englisch, S; Feyerabend, S; Gaebel, W; Gouzoulis-Mayfrank, E; Gründer, G; Hasan, A; Heres, S; Jäger, M; Kluge, M; Kolbe, H; Lange, C; Langguth, B; Leucht, S; Makiol, C; Meisenzahl-Lechner, E; Neff, A; Poeppl, T; Reske, D; Riesbeck, M; Schmidt-Kraepelin, C; Verde, PE; Wobrock, T; Zink, M, 2020) |
| " Nine patients discontinued treatment because of adverse events." | 2.82 | The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study. ( Cao, C; Chen, Z; Deng, H; Dong, F; Gao, M; Hong, L; Li, X; Li, Y; Liang, Y; Liu, T; Lu, S; Su, L; Tang, J; Tang, M; Wang, C; Wang, X; Xie, S; Xin, L; Xu, X; Yang, F; Yu, J; Yu, X; Zhang, C; Zhang, Y; Zhu, C, 2016) |
| "We have investigated the categorical prevalence of hyperprolactinemia and examined the relationship between prolactin levels and subjective endocrine-related adverse effects in schizophrenia patients treated with amisulpride during a 1-year period." | 2.77 | Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. ( Ahn, YM; Jung, DC; Kim, EY; Kim, SH; Kim, YS; Lee, NY, 2012) |
| "Tremor and insomnia were more frequent with amisulpride, while olanzapine caused more weight gain and sedation." | 2.75 | Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. ( Bhowmick, S; Ghosh, M; Hazra, A, 2010) |
| "The trial was a prospective, open-label, single-center one with a flexible dosing of SGAs." | 2.73 | Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. ( Cejpková, A; Rodáková, I; Svestka, J; Synek, O; Tomanová, J, 2007) |
| " Analyses of CFA-derived factor scores showed that ASP was significantly superior to FPX regarding the latent 'depressive' dimension, independent of baseline scores, dosage and changes in akinesia." | 2.70 | Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis. ( Benkert, O; Müller, MJ; Wetzel, H, 2002) |
| "Flupenthixol treatment initially raised the prolactin levels about two- or threefold, and a subsequent decline during months 3 and 6 occurred." | 2.70 | Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. ( Anghelescu, I; Benkert, O; Ewald-Gründer, S; Gründer, G; Hiemke, C; Hillert, A; Schlösser, R, 2002) |
| "The present analysis investigated symptom-specific dose-response relationships of the atypical antipsychotic amisulpride (AMI) in schizophrenic patients." | 2.70 | Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. ( Benkert, O; Eich, FX; Müller, MJ; Puech, A; Rein, W; Wetzel, H, 2002) |
| "This 4-week, double-blind, randomized study was undertaken to determine the dose-response relationship of amisulpride in 319 patients with acute exacerbation of schizophrenia." | 2.69 | Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. ( Fleurot, O; Puech, A; Rein, W, 1998) |
| " The drug had only a limited effect in reducing negative symptoms, which were relatively stable, enduring phenomena in this sample, despite dosage reduction." | 2.68 | One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. ( Alberts, JL; Barnes, TR; Curson, DA; Pantelis, C; Speller, JC, 1997) |
| "Schizophrenia is a mental illness causing disordered beliefs, ideas and sensations." | 2.50 | Cannabis and schizophrenia. ( Gillies, D; Kalakouti, E; Kyprianou, K; McLoughlin, BC; Pushpa-Rajah, JA; Rathbone, J; Variend, H, 2014) |
| " anticholinergics and antiparkinsonian agents) until the effective dosage has been reached." | 2.44 | Practical issues with amisulpride in the management of patients with schizophrenia. ( Alptekin, K; Kontaxakis, VP; Pani, L; Villagrán, JM, 2008) |
| " It includes concepts of human neurobiology and neuropharmacology and their application to clinical medicine, as well as the presentation of the clinical evidence on the therapeutic efficacy and safety of amisulpride in schizophrenia, highlighting dosage issues." | 2.41 | Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia. ( Kasper, S, 2002) |
| " Safety was monitored by open adverse event reporting, the Simpson-Angus Scale, the Barnes Akathisia Scale and the Abnormal Involuntary Movement scale." | 2.41 | Safety profile of amisulpride in short- and long-term use. ( Coulouvrat, C; Dondey-Nouvel, L; Rein, W, 2000) |
| "In the long term treatment of schizophrenia, amisulpride maintained antipsychotic efficacy over a 12-month period in an open randomized study." | 2.41 | Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation? ( Blin, O, 2000) |
| " In patients with acute exacerbations of schizophrenia, the recommended dosage of amisulpride is 400 to 800 mg/day, although dosages < or =1200 mg/day may be administered." | 2.41 | Amisulpride: a review of its use in the management of schizophrenia. ( Curran, MP; Perry, CM, 2001) |
| "Schizophrenia is associated with significant social, psychological and occupational dysfunction." | 2.41 | Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. ( Loo, H; Olié, JP; Saleem, P, 2002) |
| " In patients with acute exacerbations of schizophrenia, the recommended dosage of amisulpride is 400 to 800 mg/day, although dosages < or = 1200 mg/day may be administered." | 2.41 | Spotlight on amisulpride in schizophrenia. ( Curran, MP; Perry, CM, 2002) |
| "It appears to be an effective agent in treating schizophrenia for what are characterised as positive and negative symptoms." | 2.41 | Focus on amisulpride. ( Green, B, 2002) |
| " Safety data collection was performed using open reporting, UKU scales or specific extrapyramidal side-effect scales; electrocardiogram recording and vital signs examination; laboratory data collection." | 2.40 | Safety of amisulpride (Solian): a review of 11 clinical studies. ( Coulouvrat, C; Dondey-Nouvel, L, 1999) |
| "Schizophrenia is a chronic mental illness presented by cognitive deficits that precede its positive and negative symptoms." | 1.91 | Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. ( Abdelfattah, AM; Abuelezz, SA; Hendawy, N; Khalil, AMM; Nawishy, SAEK; Negm, EA, 2023) |
| "Relapse was determined by assessing changes in Positive and Negative Syndrome Scale (PANSS) total scores from baseline to 6 months (increased over 20% or 10% reaching 70)." | 1.91 | Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics. ( Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y, 2023) |
| "Retrospective studies using spontaneous reporting system databases have provided a great understanding of adverse drug reactions (ADRs) in the real world, complementing the data obtained from randomized controlled trials." | 1.72 | Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019. ( Byeon, SJ; Chung, SJ; Oh, S, 2022) |
| " Recommended dosage regimens for patients with key covariates were estimated on the basis of Monte Carlo simulations and the established model." | 1.62 | Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level. ( Huang, S; Li, L; Li, X; Liu, S; Lu, H; Shang, D; Wang, Z; Wen, Y; Xiao, T; Zhang, M, 2021) |
| "The pharmacological treatment of schizophrenia is often performed with the simultaneous use of two or more antipsychotic agents to achieve the desired control of psychotic symptoms Available AP include both conventional (typical) and new (atypical) antipsychotic medications." | 1.56 | Identification and Quantification of Antipsychotics in Blood Samples by LC-MS-MS: Case Reports and Data from Three Years of Routine Analysis. ( Claro, A; Corte-Real, F; Franco, J; Monteiro, C; Mustra, C; Proença, P, 2020) |
| "Six weeks of individually dosed amisulpride treatment." | 1.43 | Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment. ( Ebdrup, BH; Glenthøj, B; Nielsen, MØ; Rostrup, E; Wulff, S, 2016) |
| "Aripiprazole is a first or second line treatment frequently used because it has reduced side effects such as weight gain, sleepiness, dyslipidemia, insulin resistance, hyperprolactinemia and extrapyramidal symptoms." | 1.43 | [Aripiprazole, gambling disorder and compulsive sexuality]. ( Dafreville, C; Mété, D; Paitel, V; Wind, P, 2016) |
| "Amisulpride is used for the treatment of schizophrenia and part of its safety profile is that is has no effect on the QT interval in therapeutic doses." | 1.36 | Amisulpride overdose: suggested management of prolonged QTc. ( Stevenson, RJ, 2010) |
| " Hitherto under-recognised toxic effects of novel chemotherapeutic agents can pose challenges for the forensic pathologist charged with performing medico-legal autopsies in cases of sudden unexpected death in young adults and particularly in those with schizophrenia." | 1.35 | Fatality due to amisulpride toxicity: a case report. ( George, N; Gerostamoulos, D; Lynch, MJ; Woods, J, 2008) |
| "Antipsychotic drugs are the mainstay of treatment in schizophrenia." | 1.35 | Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases. ( Akkaya, C; Ersoy, C; Kaya, B; Kirli, S; Kotan, Z; Sarandol, A, 2009) |
| "Schizophrenia is a severe mental disorder that requires lifelong treatment, and therefore information on the cardiovascular safety and tolerance of antipsychotics is of significant clinical importance." | 1.35 | Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine. 3-month follow-up. ( Bai, YM; Kuo, TB; Wang, YC; Yang, CC, 2008) |
| "Although schizophrenia affects all age groups, late or very-late-onset schizophrenia-like psychosis has not been well studied and various treatment issues remain unresolved." | 1.35 | Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis. ( Papadimitriou, GN; Paparrigopoulos, TJ; Politis, AM; Psarros, C; Theleritis, CG, 2009) |
| " Preclinical evidence shows that chronic administration of antipsychotics can cause pituitary adenomas in female mice." | 1.34 | Atypical antipsychotics and pituitary neoplasms in the WHO database. ( Doraiswamy, PM; Edwards, R; Mueller-Oerlinghausen, B; Schott, G; Star, K, 2007) |
| "Risperidone monotherapy treatment was associated with hyperprolactinaemia in 69% of patients ( n = 35) and in 100% of female patients (n = 16) and amisulpride monotherapy in 100% (n = 7)." | 1.34 | Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. ( Bushe, C; Shaw, M, 2007) |
| "The galactorrhea is one of the possible side effects of psychotropic drugs." | 1.33 | [Endocrine side effects among psychiatric patients treated with antipsychotics]. ( Kovács, G; Kovács, L, 2006) |
| "Treatment with olanzapine was also associated with a higher frequency of remission compared with other antipsychotic agents." | 1.33 | Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. ( Alonso, J; Haro, JM; Lépine, JP; Novick, D; Ratcliffe, M; Suarez, D, 2006) |
| " However, no correlation between prolactin levels and dosage could be found." | 1.32 | [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. ( Fric, M; Laux, G, 2003) |
| " This allows the dosage to be adjusted and the treatment tailored to various clinical situations." | 1.32 | Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study. ( Linden, M; Scheel, T; Xaver Eich, F, 2004) |
| "The acute phase of schizophrenia is characterized by the presence of positive, negative and affective symptoms." | 1.31 | Acute phase of schizophrenia: impact of atypical antipsychotics. ( Azorin, JM, 2000) |
| "Susceptibility for malignant hyperthermia was detected by a positive in vitro contracture test." | 1.31 | [Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy]. ( Grohmann, R; Pedrosa Gil, F; Rüther, E; Schneider, C, 2001) |
| " Whether this bipolar activity is due to the play of different kinds of receptors according to the dosage used, or is due to the dopaminergic blockade in different brain areas related to the dosage remains a problem to be solved." | 1.27 | [Efficacy of low doses of atypical neuroleptics (benzamides) in defect states]. ( Boyer, P, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (1.56) | 18.7374 |
| 1990's | 21 (6.54) | 18.2507 |
| 2000's | 148 (46.11) | 29.6817 |
| 2010's | 110 (34.27) | 24.3611 |
| 2020's | 37 (11.53) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, S | 1 |
| Li, L | 4 |
| Wang, Z | 2 |
| Xiao, T | 1 |
| Li, X | 2 |
| Liu, S | 1 |
| Zhang, M | 1 |
| Lu, H | 1 |
| Wen, Y | 1 |
| Shang, D | 1 |
| Yuan, B | 1 |
| Yuan, M | 1 |
| Schmidt-Kraepelin, C | 3 |
| Feyerabend, S | 3 |
| Engelke, C | 2 |
| Riesbeck, M | 3 |
| Meisenzahl-Lechner, E | 2 |
| Verde, PE | 2 |
| Correll, CU | 2 |
| Kluge, M | 2 |
| Makiol, C | 2 |
| Neff, A | 2 |
| Lange, C | 2 |
| Englisch, S | 4 |
| Zink, M | 6 |
| Langguth, B | 3 |
| Poeppl, TB | 1 |
| Reske, D | 2 |
| Gouzoulis-Mayfrank, E | 2 |
| Gründer, G | 7 |
| Hasan, A | 2 |
| Brockhaus-Dumke, A | 2 |
| Jäger, M | 3 |
| Baumgärtner, J | 2 |
| Leucht, S | 26 |
| Cordes, J | 4 |
| Zheng, J | 1 |
| Lin, Z | 1 |
| Ko, CY | 1 |
| Xu, JH | 1 |
| Lin, Y | 1 |
| Wang, J | 1 |
| Oh, S | 1 |
| Byeon, SJ | 1 |
| Chung, SJ | 1 |
| Mørkved, N | 1 |
| Johnsen, E | 4 |
| Kroken, RA | 4 |
| Winje, D | 1 |
| Larsen, TK | 2 |
| Thimm, JC | 1 |
| Rettenbacher, MA | 5 |
| Johannesen, CAB | 1 |
| Løberg, EM | 3 |
| Qu, K | 1 |
| Zhou, Q | 1 |
| Tian, L | 1 |
| Shen, Y | 2 |
| Zhou, Z | 1 |
| Heres, S | 4 |
| Musil, R | 2 |
| Riedel, M | 3 |
| Spellmann, I | 1 |
| Landgrebe, M | 1 |
| Fran, E | 1 |
| Petcu C, C | 1 |
| Hahn, E | 1 |
| Ta, TMT | 1 |
| Matei, V | 1 |
| Dehelean, L | 1 |
| Papava, I | 1 |
| Leweke, FM | 4 |
| van der List, T | 1 |
| Tamasan, SC | 1 |
| Lang, FU | 1 |
| Naber, D | 6 |
| Ruhrmann, S | 2 |
| Wolff-Menzler, C | 1 |
| Juckel, G | 3 |
| Ladea, M | 1 |
| Stefanescu, C | 1 |
| Lautenschlager, M | 1 |
| Bauer, M | 1 |
| Zamora, D | 1 |
| Horowitz, M | 1 |
| Davis, JM | 6 |
| Zhu, MH | 1 |
| Liu, ZJ | 1 |
| Hu, QY | 1 |
| Yang, JY | 1 |
| Jin, Y | 1 |
| Zhu, N | 1 |
| Huang, Y | 2 |
| Shi, DH | 1 |
| Liu, MJ | 1 |
| Tan, HY | 1 |
| Zhao, L | 1 |
| Lv, QY | 1 |
| Yi, ZH | 1 |
| Wu, FC | 1 |
| Li, ZZ | 1 |
| de Bartolomeis, A | 1 |
| Ciccarelli, M | 1 |
| Vellucci, L | 1 |
| Fornaro, M | 1 |
| Iasevoli, F | 1 |
| Barone, A | 1 |
| de Haan, L | 2 |
| van Tricht, M | 2 |
| van Dijk, F | 2 |
| Arango, C | 5 |
| Díaz-Caneja, CM | 4 |
| Bobes, J | 3 |
| García-Álvarez, L | 2 |
| Abdelfattah, AM | 1 |
| Abuelezz, SA | 1 |
| Hendawy, N | 1 |
| Negm, EA | 1 |
| Nawishy, SAEK | 1 |
| Khalil, AMM | 1 |
| Yang, S | 1 |
| Wang, H | 1 |
| Zheng, GF | 1 |
| Wang, Y | 1 |
| Cai, J | 2 |
| Shao, T | 1 |
| Sun, M | 1 |
| Wang, W | 1 |
| Xie, P | 1 |
| Wang, X | 4 |
| Yang, Y | 3 |
| Long, Y | 2 |
| Kang, D | 1 |
| Xiao, J | 2 |
| Su, Y | 1 |
| Peng, X | 1 |
| Gao, M | 2 |
| Wu, Q | 2 |
| Song, C | 1 |
| Liu, F | 2 |
| Shao, P | 1 |
| Ou, J | 1 |
| Huang, J | 1 |
| Wu, R | 2 |
| Stabell, LA | 1 |
| Blindheim, A | 1 |
| Joa, I | 2 |
| Reitan, SK | 2 |
| Rettenbacher, M | 2 |
| Munk-Jørgensen, P | 1 |
| Gjestad, R | 1 |
| Liu, Z | 2 |
| Xu, Y | 1 |
| Chen, Y | 2 |
| Huang, M | 1 |
| Zhang, R | 1 |
| Xu, X | 2 |
| Hu, J | 1 |
| Zheng, Y | 1 |
| Meng, H | 1 |
| Tang, Y | 1 |
| Song, X | 1 |
| Liu, T | 2 |
| Wu, X | 1 |
| Fang, M | 1 |
| Wan, C | 1 |
| Zhao, J | 1 |
| Gaebel, W | 4 |
| Kolbe, H | 1 |
| Poeppl, T | 1 |
| Wobrock, T | 1 |
| Luykx, JJ | 3 |
| Kraats, GV | 1 |
| van Ojen, R | 1 |
| McCutcheon, RA | 1 |
| Reis Marques, T | 1 |
| Howes, OD | 1 |
| Shang, DW | 1 |
| Wen, YG | 1 |
| Ning, YP | 1 |
| Ter Hark, SE | 2 |
| Jamain, S | 1 |
| Schijven, D | 1 |
| Lin, BD | 1 |
| Bakker, MK | 1 |
| Boland-Auge, A | 1 |
| Deleuze, JF | 1 |
| Troudet, R | 1 |
| Malhotra, AK | 1 |
| Gülöksüz, S | 2 |
| Vinkers, CH | 2 |
| Ebdrup, BH | 8 |
| Kahn, RS | 10 |
| Leboyer, M | 3 |
| Yi, ZM | 1 |
| Men, P | 2 |
| Qu, S | 2 |
| Li, C | 2 |
| Yu, X | 4 |
| Zhai, S | 2 |
| Yuan, T | 1 |
| Wang, S | 1 |
| Le, J | 1 |
| Li, Y | 2 |
| Baandrup, L | 2 |
| Allerup, P | 2 |
| Nielsen, MØ | 7 |
| Bak, N | 4 |
| Düring, SW | 3 |
| Galderisi, S | 4 |
| Mucci, A | 2 |
| Bucci, P | 2 |
| Dazzan, P | 2 |
| McGuire, P | 3 |
| Demjaha, A | 1 |
| Glenthøj, BY | 7 |
| Ruiz-Doblado, S | 1 |
| Plasencia-García de Diego, B | 1 |
| Perea-Pérez, R | 1 |
| Jiménez-Gonzalo, F | 1 |
| Kopelli, E | 1 |
| Samara, M | 2 |
| Siargkas, A | 1 |
| Goulas, A | 1 |
| Papazisis, G | 1 |
| Chourdakis, M | 1 |
| Proença, P | 1 |
| Monteiro, C | 1 |
| Mustra, C | 1 |
| Claro, A | 1 |
| Franco, J | 1 |
| Corte-Real, F | 1 |
| Wang, G | 1 |
| Zhou, B | 1 |
| Zheng, L | 1 |
| Ni, Y | 1 |
| Pan, A | 1 |
| Walla, B | 1 |
| Alisauskiene, R | 1 |
| Anda, LG | 1 |
| Bartz-Johannessen, C | 1 |
| Berle, JØ | 1 |
| Bjarke, J | 1 |
| Fathian, F | 1 |
| Hugdahl, K | 1 |
| Kjelby, E | 1 |
| Sinkeviciute, I | 1 |
| Skrede, S | 1 |
| Stabell, L | 1 |
| Steen, VM | 2 |
| Fleischhacker, WW | 10 |
| Ji, JW | 1 |
| Liu, LY | 1 |
| Hao, KR | 1 |
| Yu, YL | 1 |
| Weng, SZ | 1 |
| Wu, JF | 1 |
| Huang, RC | 1 |
| Hadryś, T | 1 |
| Rymaszewska, J | 1 |
| Zhenhua, W | 1 |
| Haizhi, C | 1 |
| Jing, L | 1 |
| Xiaocong, F | 1 |
| Jianhua, L | 1 |
| Jianjun, L | 1 |
| Lilei, L | 1 |
| Haiying, J | 1 |
| Hopkins, SC | 1 |
| Wilkinson, S | 1 |
| Corriveau, TJ | 1 |
| Nishikawa, H | 1 |
| Nakamichi, K | 1 |
| Loebel, A | 1 |
| Koblan, KS | 1 |
| Sun, F | 1 |
| Yu, F | 1 |
| Gao, Z | 1 |
| Ren, Z | 1 |
| Jin, W | 1 |
| Kang, SG | 3 |
| Chee, IS | 3 |
| Lee, K | 3 |
| Lee, J | 3 |
| Barber, S | 1 |
| Olotu, U | 1 |
| Corsi, M | 1 |
| Cipriani, A | 3 |
| Oranje, B | 3 |
| Fagerlund, B | 1 |
| Jensen, MH | 1 |
| Hansen, LK | 1 |
| Reeves, S | 2 |
| Eggleston, K | 1 |
| Cort, E | 2 |
| McLachlan, E | 1 |
| Brownings, S | 1 |
| Nair, A | 1 |
| Greaves, S | 1 |
| Smith, A | 1 |
| Dunn, J | 1 |
| Marsden, P | 1 |
| Kessler, R | 1 |
| Taylor, D | 2 |
| Bertrand, J | 1 |
| Howard, R | 2 |
| Barnes, TR | 2 |
| Leeson, VC | 1 |
| Paton, C | 1 |
| Marston, L | 1 |
| Davies, L | 1 |
| Whittaker, W | 1 |
| Osborn, D | 1 |
| Kumar, R | 1 |
| Keown, P | 1 |
| Zafar, R | 1 |
| Iqbal, K | 1 |
| Singh, V | 1 |
| Fridrich, P | 1 |
| Fitzgerald, Z | 1 |
| Bagalkote, H | 1 |
| Haddad, PM | 1 |
| Husni, M | 1 |
| Amos, T | 1 |
| Chang, HS | 1 |
| Na, KS | 2 |
| Gowda, GS | 1 |
| Sastry Nagavarapu, LS | 1 |
| Reddy Mukku, SS | 1 |
| Farooq Ali, S | 1 |
| Colle, R | 1 |
| Boichot, F | 1 |
| Bouteiller, E | 1 |
| Elie-Lefebvre, C | 1 |
| Hardy, P | 1 |
| David, DJ | 1 |
| Verstuyft, C | 1 |
| Corruble, E | 1 |
| Cevher Binici, N | 1 |
| Topal, Z | 1 |
| Demir Samurcu, N | 1 |
| Cansız, MA | 1 |
| Savcı, U | 1 |
| Öztürk, Y | 1 |
| Özyurt, G | 1 |
| Tufan, AE | 1 |
| Gao, LJ | 1 |
| Guo, HG | 1 |
| Liang, ZT | 1 |
| Zhong, XX | 1 |
| Zhu, JC | 1 |
| Zipursky, RB | 1 |
| Winter van Rossum, I | 1 |
| Lewis, SW | 1 |
| Drake, R | 1 |
| Rujescu, D | 2 |
| Weiser, M | 1 |
| Glenthøj, B | 4 |
| Eijkemans, MJC | 1 |
| Kapur, S | 5 |
| Sommer, IE | 3 |
| Cho, SJ | 1 |
| Kim, MK | 1 |
| Bang, SY | 1 |
| Bang, M | 1 |
| Lee, SH | 2 |
| Yi, Z | 1 |
| Xiong, T | 1 |
| Heriot-Maitland, C | 1 |
| Allan, S | 1 |
| Bradstreet, S | 1 |
| Gumley, A | 1 |
| Smith, RC | 1 |
| Bradley, R | 1 |
| Harper, E | 1 |
| Kelly, L | 1 |
| Bentham, P | 1 |
| Ritchie, C | 1 |
| Fawzi, W | 1 |
| Livingston, G | 1 |
| Sommerlad, A | 1 |
| Oomman, S | 1 |
| Nazir, E | 1 |
| Nilforooshan, R | 1 |
| Barber, R | 1 |
| Fox, C | 1 |
| Macharouthu, A | 1 |
| Ramachandra, P | 1 |
| Pattan, V | 1 |
| Sykes, J | 1 |
| Curran, V | 1 |
| Katona, C | 1 |
| Dening, T | 1 |
| Knapp, M | 2 |
| Romeo, R | 1 |
| Gray, R | 1 |
| Wulff, S | 3 |
| Rostrup, E | 4 |
| Svarer, C | 2 |
| Jensen, LT | 2 |
| Pinborg, L | 1 |
| Pandit, R | 1 |
| Cianci, D | 1 |
| Winter-van Rossum, I | 2 |
| Broberg, BV | 1 |
| Garcia-Portilla, MP | 1 |
| Huitema, ADR | 1 |
| Chang, CK | 1 |
| Hung, GC | 2 |
| Takács, R | 1 |
| Iványi, Z | 1 |
| Ungvari, GS | 1 |
| Gazdag, G | 1 |
| Vetlugina, TP | 2 |
| Lobacheva, OA | 2 |
| Al'perina, EL | 2 |
| Zhukova, EN | 2 |
| Semke, AV | 1 |
| Nikitina, VB | 1 |
| Cheĭdo, MA | 2 |
| Idova, GV | 2 |
| Nikiforuk, A | 2 |
| Kos, T | 1 |
| Fijał, K | 1 |
| Hołuj, M | 2 |
| Rafa, D | 1 |
| Popik, P | 2 |
| Lin, CH | 1 |
| Wang, FC | 1 |
| Lin, SC | 1 |
| Huang, YH | 1 |
| Chen, CC | 3 |
| Lane, HY | 1 |
| Kalkavoura, CS | 1 |
| Michopoulos, I | 1 |
| Arvanitakis, P | 1 |
| Theodoropoulou, P | 1 |
| Dimopoulou, K | 1 |
| Tzebelikos, E | 1 |
| Lykouras, L | 2 |
| Meniavtseva, TA | 1 |
| Grassi, G | 1 |
| Poli, L | 1 |
| Cantisani, A | 1 |
| Righi, L | 1 |
| Ferrari, G | 1 |
| Pallanti, S | 1 |
| Volavka, J | 2 |
| Czobor, P | 2 |
| Citrome, L | 1 |
| Van Dorn, RA | 1 |
| Hotham, JE | 1 |
| Simpson, PJ | 1 |
| Brooman-White, RS | 1 |
| Basu, A | 1 |
| Ross, CC | 1 |
| Humphreys, SA | 1 |
| Larkin, F | 1 |
| Gupta, N | 1 |
| Das, M | 1 |
| Rafrafi, R | 1 |
| Abdelaghaffar, W | 1 |
| Ouanes, S | 1 |
| Bekri, I | 1 |
| Melki, W | 1 |
| El Hechmi, Z | 1 |
| Lai, EC | 1 |
| Hsieh, CY | 1 |
| Kao Yang, YH | 1 |
| Lin, SJ | 1 |
| Levine, SZ | 5 |
| Düring, S | 2 |
| Andersen, GS | 1 |
| Cheng, CM | 1 |
| Tsai, SJ | 2 |
| Schirmbeck, F | 2 |
| Mier, D | 1 |
| Esslinger, C | 2 |
| Rausch, F | 2 |
| Eifler, S | 1 |
| Meyer-Lindenberg, A | 4 |
| Kirsch, P | 1 |
| Pridan, S | 1 |
| Baruch, Y | 1 |
| Swartz, M | 1 |
| Barak, Y | 1 |
| McLoughlin, BC | 1 |
| Pushpa-Rajah, JA | 1 |
| Gillies, D | 1 |
| Rathbone, J | 1 |
| Variend, H | 1 |
| Kalakouti, E | 1 |
| Kyprianou, K | 1 |
| Porcelli, S | 1 |
| Serretti, A | 1 |
| Bianchini, O | 1 |
| Furukawa, TA | 1 |
| Tanaka, S | 1 |
| Goldberg, Y | 1 |
| Toledo-Romero, F | 2 |
| Molina, JD | 3 |
| López-Rodríguez, E | 2 |
| Amorin-Díaz, M | 2 |
| Muñoz Algar, MJ | 1 |
| Aparicio-Castro, E | 1 |
| Chuang, WC | 1 |
| Chen, CY | 3 |
| Kuo, SC | 3 |
| Chen, TY | 1 |
| Yeh, YW | 3 |
| Dimitrakopoulou, V | 1 |
| Efthimiou, O | 1 |
| Salanti, G | 1 |
| Lee, HJ | 1 |
| Pinborg, LH | 1 |
| Rasmussen, H | 1 |
| Frandsen, E | 1 |
| Lewis, S | 1 |
| Laoutidis, ZG | 1 |
| Konstantinidis, A | 1 |
| Grohmann, R | 2 |
| Luckhaus, C | 1 |
| Mobascher, J | 1 |
| Tracy, DK | 1 |
| Joyce, DW | 1 |
| Sarkar, SN | 1 |
| Mateos Fernandez, MJ | 1 |
| Shergill, SS | 1 |
| Liang, Y | 2 |
| Su, YA | 1 |
| Zhao, ZG | 1 |
| Gao, N | 1 |
| Huang, JZ | 1 |
| Tang, MQ | 1 |
| Li, KQ | 1 |
| Yang, FD | 1 |
| Si, TM | 1 |
| Lee, CP | 1 |
| Chen, PJ | 1 |
| Chang, CM | 1 |
| Rogdaki, M | 1 |
| Jauhar, S | 1 |
| McCutcheon, R | 1 |
| Howes, O | 1 |
| Raghava, JM | 1 |
| Bonnet, U | 1 |
| Taazimi, B | 1 |
| Montag, M | 1 |
| Ronge, R | 1 |
| Gespers, H | 1 |
| Kuhlmann, R | 1 |
| Grabbe, D | 1 |
| Jahn, J | 1 |
| Ho, PS | 1 |
| Liang, CS | 1 |
| Yen, CH | 1 |
| Lu, RB | 1 |
| Huang, SY | 2 |
| Mété, D | 1 |
| Dafreville, C | 1 |
| Paitel, V | 1 |
| Wind, P | 1 |
| Hema, T | 1 |
| Maran, S | 1 |
| Subhashini, G | 1 |
| Sinha, P | 1 |
| Garg, A | 1 |
| Karbownik, MS | 1 |
| Szemraj, J | 1 |
| Wieteska, Ł | 1 |
| Antczak, A | 1 |
| Górski, P | 1 |
| Kowalczyk, E | 1 |
| Pietras, T | 1 |
| Cao, C | 1 |
| Zhu, C | 1 |
| Wang, C | 1 |
| Zhang, C | 1 |
| Dong, F | 1 |
| Yang, F | 1 |
| Deng, H | 1 |
| Yu, J | 1 |
| Tang, J | 1 |
| Su, L | 1 |
| Xin, L | 1 |
| Hong, L | 1 |
| Tang, M | 1 |
| Xie, S | 1 |
| Lu, S | 1 |
| Zhang, Y | 1 |
| Chen, Z | 1 |
| Su, CH | 1 |
| Chen, CS | 1 |
| Huang, MF | 1 |
| Sampford, JR | 1 |
| Sampson, S | 1 |
| Li, BG | 1 |
| Zhao, S | 1 |
| Xia, J | 1 |
| Furtado, VA | 1 |
| Bas, A | 1 |
| Gultekin, G | 1 |
| Incir, S | 1 |
| Bas, TO | 1 |
| Emul, M | 1 |
| Duran, A | 1 |
| Lynch, MJ | 1 |
| Woods, J | 1 |
| George, N | 1 |
| Gerostamoulos, D | 1 |
| Akkaya, C | 1 |
| Kaya, B | 1 |
| Kotan, Z | 1 |
| Sarandol, A | 1 |
| Ersoy, C | 1 |
| Kirli, S | 1 |
| Müller, MJ | 5 |
| Eich, FX | 9 |
| Regenbogen, B | 3 |
| Sachse, J | 2 |
| Härtter, S | 4 |
| Hiemke, C | 6 |
| Chen, HK | 1 |
| Chen, CK | 3 |
| Tzeng, NS | 1 |
| Pani, L | 4 |
| Villagrán, JM | 1 |
| Kontaxakis, VP | 2 |
| Alptekin, K | 1 |
| Mendhekar, DN | 2 |
| Yajuvendra, B | 1 |
| Aggarwal, A | 1 |
| Wang, YC | 1 |
| Yang, CC | 1 |
| Bai, YM | 1 |
| Kuo, TB | 1 |
| Baier, PC | 1 |
| Koch, JM | 1 |
| Seeck-Hirschner, M | 1 |
| Ohlmeyer, K | 1 |
| Wilms, S | 1 |
| Aldenhoff, JB | 2 |
| Hinze-Selch, D | 1 |
| Meisenzahl, EM | 1 |
| Schmitt, G | 2 |
| Dresel, S | 2 |
| Frodl, T | 2 |
| la Fougère, C | 2 |
| Scheuerecker, J | 1 |
| Schwarz, M | 1 |
| Boerner, R | 1 |
| Stauss, J | 2 |
| Hahn, K | 2 |
| Möller, HJ | 13 |
| Psarros, C | 1 |
| Theleritis, CG | 2 |
| Paparrigopoulos, TJ | 1 |
| Politis, AM | 1 |
| Papadimitriou, GN | 3 |
| Harangozó, J | 2 |
| Slezák, A | 2 |
| Borsos, K | 2 |
| Németh, O | 2 |
| Csukly, G | 1 |
| Chen, CL | 1 |
| Tschoner, A | 1 |
| Engl, J | 1 |
| Kaser, S | 1 |
| Ott, HW | 1 |
| Patsch, JR | 1 |
| Ebenbichler, CF | 1 |
| Varol Tas, F | 1 |
| Guvenir, T | 1 |
| Barceló, B | 1 |
| Yates, C | 1 |
| Castanyer, B | 1 |
| Puiguriguer, J | 1 |
| Goldberg, TE | 1 |
| Gomar, JJ | 1 |
| Ahn, YM | 5 |
| Lee, KY | 3 |
| Kim, CE | 2 |
| Kim, JJ | 1 |
| Kang, DY | 2 |
| Jun, TY | 2 |
| Choi, JS | 1 |
| Chung, IW | 2 |
| Kim, SH | 4 |
| Hwang, SS | 3 |
| Kim, YS | 5 |
| Chang, JS | 2 |
| Sparshatt, A | 1 |
| Patel, MX | 1 |
| Boso, M | 1 |
| Barbui, C | 1 |
| Komossa, K | 5 |
| Rummel-Kluge, C | 5 |
| Hunger, H | 5 |
| Schwarz, S | 5 |
| Bhoopathi, PS | 1 |
| Kissling, W | 8 |
| Lambert, M | 2 |
| Schimmelmann, BG | 2 |
| Schulz, H | 1 |
| Huber, CG | 1 |
| Karow, A | 1 |
| Bhowmick, S | 1 |
| Hazra, A | 1 |
| Ghosh, M | 1 |
| Jung, DC | 2 |
| Schmid, F | 4 |
| Silveira da Mota Neto, JI | 1 |
| Nuss, P | 2 |
| Tessier, C | 1 |
| Hoyer, C | 2 |
| Kranaster, L | 1 |
| Klosterkötter, J | 3 |
| Koethe, D | 2 |
| von Wilmsdorff, M | 1 |
| Burns, T | 2 |
| Derks, EM | 2 |
| Rössler, W | 1 |
| Rizos, EN | 1 |
| Papadopoulou, A | 1 |
| Laskos, E | 1 |
| Michalopoulou, PG | 1 |
| Kastania, A | 1 |
| Vasilopoulos, D | 1 |
| Katsafouros, K | 1 |
| Duggan, L | 1 |
| Goyal, N | 1 |
| Sinha, VK | 1 |
| Chen, YY | 1 |
| Pehlivanidis, A | 1 |
| Spyropoulou, AC | 1 |
| Tourkantonis, A | 1 |
| Müller, N | 1 |
| Krause, D | 1 |
| Dehning, S | 1 |
| Schennach-Wolff, R | 1 |
| Obermeier, M | 1 |
| Klauss, V | 1 |
| Schwarz, MJ | 1 |
| Stevenson, RJ | 1 |
| Andrade, C | 1 |
| Li, TC | 2 |
| Chiu, HW | 2 |
| Liu, HH | 1 |
| Lobos, CA | 1 |
| Teoh, S | 1 |
| Ilett, KF | 1 |
| Hackett, LP | 1 |
| Kohan, R | 1 |
| Kreinin, A | 2 |
| Miodownik, C | 1 |
| Sokolik, S | 1 |
| Shestakova, D | 1 |
| Libov, I | 1 |
| Bergman, J | 1 |
| Lerner, V | 1 |
| Moons, T | 1 |
| Claes, S | 1 |
| Martens, GJ | 1 |
| Peuskens, J | 10 |
| Van Loo, KM | 1 |
| Van Schijndel, JE | 1 |
| De Hert, M | 2 |
| van Winkel, R | 1 |
| Quintero, J | 1 |
| Barbudo, E | 1 |
| Mur, C | 1 |
| Ceverino, A | 1 |
| Garcia-Resa, E | 1 |
| Correas Lauffer, J | 1 |
| Dietrich-Muszalska, A | 1 |
| Olas, B | 1 |
| Kontek, B | 1 |
| Rabe-Jabłońska, J | 1 |
| Lerma-Carrillo, I | 1 |
| López-Muñoz, F | 1 |
| Stratos, AA | 1 |
| Peponis, VG | 1 |
| Portaliou, DM | 1 |
| Stroubini, TE | 1 |
| Skouriotis, S | 1 |
| Kymionis, GD | 1 |
| Bitter, I | 3 |
| Libiger, J | 3 |
| Ku, YC | 1 |
| Huang, HT | 1 |
| Seok, JH | 1 |
| Shin, YM | 1 |
| Kucharska-Pietura, K | 1 |
| Tylec, A | 1 |
| Czernikiewicz, A | 1 |
| Mortimer, A | 3 |
| Kuo, CJ | 1 |
| Yang, SY | 1 |
| Liao, YT | 1 |
| Chen, WJ | 1 |
| Lee, WC | 1 |
| Shau, WY | 1 |
| Chang, YT | 1 |
| Tsai, SY | 1 |
| Jeong, HG | 1 |
| Lee, MS | 1 |
| Lee, HY | 1 |
| Ko, YH | 1 |
| Han, C | 1 |
| Joe, SH | 1 |
| Kim, EY | 1 |
| Lee, NY | 1 |
| Hutton, P | 1 |
| Morrison, AP | 1 |
| Yung, AR | 1 |
| Taylor, PJ | 1 |
| French, P | 1 |
| Dunn, G | 1 |
| Novick, D | 2 |
| Ascher-Svanum, H | 1 |
| Brugnoli, R | 1 |
| Bertsch, J | 1 |
| Hong, J | 1 |
| Haro, JM | 2 |
| Piomelli, D | 1 |
| Pahlisch, F | 1 |
| Muhl, D | 1 |
| Gerth, CW | 1 |
| Hellmich, M | 1 |
| Yun, HW | 1 |
| Lee, BD | 1 |
| Bicikova, M | 1 |
| Hill, M | 1 |
| Ripova, D | 1 |
| Mohr, P | 1 |
| Hampl, R | 1 |
| Lee, SJ | 1 |
| Lee, JH | 2 |
| Jung, SW | 1 |
| Koo, BH | 1 |
| Choi, TY | 1 |
| Lee, KH | 1 |
| Lai, CH | 1 |
| Puech, A | 3 |
| Wetzel, H | 3 |
| Benkert, O | 4 |
| Chabannes, JP | 2 |
| Demyttenaere, K | 1 |
| Schlösser, R | 2 |
| Anghelescu, I | 2 |
| Hillert, A | 2 |
| Ewald-Gründer, S | 1 |
| Saba, G | 1 |
| Rocamora, JF | 1 |
| Kalalou, K | 1 |
| Benadhira, R | 1 |
| Plaze, M | 1 |
| Aubriot-Delmas, B | 1 |
| Januel, D | 1 |
| Lecrubier, Y | 8 |
| Martin, S | 2 |
| Lĵo, H | 1 |
| Thirumalai, S | 1 |
| Giudicelli, A | 1 |
| Fleurot, O | 7 |
| Rein, W | 11 |
| Sechter, D | 1 |
| Hwang, TJ | 1 |
| Lee, SM | 1 |
| Sun, HJ | 1 |
| Lin, HN | 1 |
| Lee, YC | 1 |
| Chen, YS | 1 |
| Kasper, S | 2 |
| Lambert, TJ | 1 |
| Castle, DJ | 1 |
| Murphy, BP | 1 |
| Bressan, RA | 3 |
| Erlandsson, K | 3 |
| Jones, HM | 1 |
| Mulligan, R | 1 |
| Flanagan, RJ | 1 |
| Ell, PJ | 3 |
| Pilowsky, LS | 3 |
| Fric, M | 1 |
| Laux, G | 1 |
| Knopf, U | 1 |
| Henn, FA | 2 |
| Thome, J | 2 |
| Mortimer, AM | 2 |
| Linden, M | 4 |
| Scheel, T | 2 |
| Xaver Eich, F | 1 |
| Spencer, EP | 1 |
| Bergemann, N | 2 |
| Kopitz, J | 2 |
| Kress, KR | 2 |
| Frick, A | 1 |
| Lôo, H | 3 |
| Agelink, MW | 2 |
| Kavuk, I | 1 |
| Ak, I | 1 |
| Grigor'eva, EA | 1 |
| Ritskov, AS | 1 |
| Racagni, G | 1 |
| Canonico, PL | 1 |
| Ravizza, L | 1 |
| Amore, M | 2 |
| Munro, J | 1 |
| Matthiasson, P | 1 |
| Osborne, S | 1 |
| Travis, M | 1 |
| Purcell, S | 1 |
| Cobb, AM | 1 |
| Launer, M | 1 |
| Beer, MD | 1 |
| Kerwin, R | 2 |
| Chou, YH | 1 |
| McKeage, K | 1 |
| Plosker, GL | 1 |
| Pogarell, O | 1 |
| Mulert, C | 1 |
| Amann, B | 1 |
| Hegerl, U | 1 |
| Nadeem, Z | 2 |
| McIntosh, A | 3 |
| Lawrie, S | 3 |
| Strasser, O | 1 |
| Schmauss, M | 1 |
| Messer, T | 1 |
| Wagner, M | 3 |
| Quednow, BB | 2 |
| Westheide, J | 2 |
| Schlaepfer, TE | 1 |
| Maier, W | 3 |
| Kühn, KU | 3 |
| Atbasoglu, EC | 1 |
| Ozguven, HD | 1 |
| Can Saka, M | 1 |
| Goker, C | 1 |
| George, S | 1 |
| Cowan, C | 1 |
| Vernaleken, I | 1 |
| Siessmeier, T | 1 |
| Buchholz, HG | 1 |
| Stoeter, P | 1 |
| Rösch, F | 1 |
| Bartenstein, P | 1 |
| Kämpf, P | 1 |
| Cook, B | 1 |
| Hoogenboom, G | 1 |
| Stone, JM | 1 |
| Kukla, B | 1 |
| Müller, JL | 1 |
| Putzhammer, A | 1 |
| Hajak, G | 1 |
| Surguladze, S | 1 |
| Patel, A | 1 |
| Kerwin, RW | 1 |
| Travis, MJ | 1 |
| Herrera-Estrella, M | 1 |
| Apiquian, R | 1 |
| Fresan, A | 1 |
| Sanchez-Torres, I | 1 |
| Meisenzahl, E | 1 |
| Tatsch, K | 1 |
| Busch, R | 1 |
| Hamann, J | 2 |
| Kane, JM | 2 |
| Brakoulias, V | 1 |
| Bannan, E | 1 |
| Cohen, P | 1 |
| Geary, G | 1 |
| Beckmann, K | 1 |
| Bliesener, N | 1 |
| Etschel, E | 1 |
| Engel, R | 1 |
| Lin, CL | 1 |
| Shiah, IS | 1 |
| Yeh, CB | 1 |
| Wan, FJ | 1 |
| Wang, TS | 1 |
| Novitski, D | 1 |
| Weizman, A | 1 |
| Olié, JP | 2 |
| Spina, E | 1 |
| Murray, S | 1 |
| Yang, R | 1 |
| Dikeos, DG | 1 |
| Psarros, CJ | 1 |
| Soldatos, CR | 2 |
| Havaki-Kontaxaki, BJ | 1 |
| Ferentinos, PP | 1 |
| Paplos, KG | 1 |
| Engel, RR | 2 |
| Bäuml, J | 1 |
| Paulzen, M | 1 |
| Ebenbichler, C | 2 |
| Hofer, A | 3 |
| Kemmler, G | 3 |
| Baumgartner, S | 2 |
| Edlinger, M | 3 |
| Hummer, M | 3 |
| Lechleitner, M | 2 |
| Quintin, P | 1 |
| Bouhassira, M | 1 |
| Perrin, E | 1 |
| Lancrenon, S | 1 |
| Wolfgang Fleischhacker, W | 1 |
| Kovács, L | 1 |
| Kovács, G | 1 |
| Suarez, D | 1 |
| Alonso, J | 1 |
| Lépine, JP | 1 |
| Ratcliffe, M | 1 |
| Vanelle, JM | 2 |
| Douki, S | 1 |
| Göder, R | 1 |
| Boigs, M | 1 |
| Braun, S | 1 |
| Koch, J | 1 |
| Fritzer, G | 1 |
| Schacht, M | 1 |
| Doraiswamy, PM | 1 |
| Schott, G | 1 |
| Star, K | 1 |
| Edwards, R | 1 |
| Mueller-Oerlinghausen, B | 1 |
| Huber, R | 1 |
| Bodner, T | 1 |
| Sachs, G | 1 |
| Limosin, F | 1 |
| Fitzgerald, PB | 1 |
| Sritharan, A | 1 |
| Benitez, J | 1 |
| Daskalakis, ZJ | 1 |
| Jackson, G | 1 |
| Kulkarni, J | 1 |
| Egan, GF | 1 |
| Peritogiannis, V | 1 |
| Goulia, P | 1 |
| Pappas, D | 1 |
| Hyphantis, T | 1 |
| Mavreas, V | 1 |
| Pyrkosch, L | 1 |
| Law, WL | 1 |
| Hui, HY | 1 |
| Young, WM | 1 |
| You, JH | 1 |
| Bushe, C | 1 |
| Shaw, M | 1 |
| Joyce, E | 1 |
| Balasubramaniam, K | 1 |
| Choudhary, PC | 1 |
| Saleem, PT | 1 |
| Kim, SW | 2 |
| Shin, IS | 2 |
| Kim, JM | 2 |
| Yoon, BH | 1 |
| Yang, SJ | 2 |
| Hwang, MY | 2 |
| Yoon, JS | 2 |
| Dervaux, A | 1 |
| Cazali, J | 1 |
| Abu-Tair, F | 1 |
| Parzer, P | 1 |
| Bazin, N | 1 |
| Leguay, D | 1 |
| Peretti, CS | 1 |
| Tatu, P | 1 |
| Hameg, A | 1 |
| Garay, RP | 1 |
| Ferreri, M | 1 |
| Bechdolf, A | 1 |
| Schultze-Lutter, F | 1 |
| Janssen, B | 1 |
| Maurer, K | 1 |
| Häfner, H | 1 |
| Svestka, J | 1 |
| Synek, O | 1 |
| Tomanová, J | 1 |
| Rodáková, I | 1 |
| Cejpková, A | 1 |
| Assion, HJ | 1 |
| Reinbold, H | 1 |
| Lemanski, S | 1 |
| Basilowski, M | 1 |
| Lang, UE | 1 |
| Willbring, M | 1 |
| von Golitschek, R | 1 |
| Schmeisser, A | 1 |
| Matschke, K | 1 |
| Malte Tugtekin, S | 1 |
| Taylor, M | 1 |
| Shajahan, P | 1 |
| Lawrie, SM | 1 |
| Boter, H | 1 |
| Davidson, M | 1 |
| Vergouwe, Y | 1 |
| Keet, IP | 1 |
| Gheorghe, MD | 1 |
| Rybakowski, JK | 1 |
| Dollfus, S | 1 |
| López-Ibor, JJ | 1 |
| Hranov, LG | 1 |
| Lindefors, N | 1 |
| Riecher-Rössler, A | 1 |
| Grobbee, DE | 1 |
| Das, PP | 1 |
| Grover, S | 1 |
| Sahoo, M | 1 |
| Mann, K | 1 |
| Bartels, M | 1 |
| Bauer, H | 1 |
| Gaertner, HJ | 2 |
| Paillère-Martinot, ML | 4 |
| Martinot, JL | 4 |
| Aubin, F | 2 |
| Duval, F | 1 |
| Mokrani, MC | 1 |
| Macher, JP | 1 |
| Crocq, MA | 1 |
| Castro, JO | 1 |
| Bailey, P | 1 |
| Lataste, X | 1 |
| Boyer, P | 4 |
| Puech, AJ | 3 |
| Dewailly, J | 1 |
| Saletu, B | 1 |
| Küfferle, B | 1 |
| Grünberger, J | 1 |
| Földes, P | 1 |
| Topitz, A | 1 |
| Anderer, P | 1 |
| Perrault, G | 2 |
| Schoemaker, H | 2 |
| Scatton, B | 2 |
| Poirier, MF | 1 |
| Dao-Castellana, MH | 1 |
| Loc'h, C | 2 |
| Mazière, B | 2 |
| Poirier-Littre, MF | 1 |
| Theron, M | 1 |
| Turjanski, S | 1 |
| Claustre, Y | 1 |
| Cudennec, A | 1 |
| Oblin, A | 1 |
| Sanger, DJ | 1 |
| Speller, JC | 1 |
| Curson, DA | 1 |
| Pantelis, C | 1 |
| Alberts, JL | 1 |
| Trichard, C | 1 |
| Attar-Levy, D | 1 |
| Recassens, C | 1 |
| Monnet, F | 1 |
| Reid, S | 1 |
| Turner, J | 1 |
| Lange, K | 1 |
| Danion, JM | 1 |
| Coulouvrat, C | 2 |
| Dondey-Nouvel, L | 3 |
| Bech, P | 1 |
| Bale, R | 1 |
| Darcourt, G | 1 |
| Colonna, L | 1 |
| Saleem, P | 2 |
| Carrière, P | 1 |
| Bonhomme, D | 1 |
| Lempérière, T | 2 |
| Geddes, J | 1 |
| Freemantle, N | 1 |
| Harrison, P | 1 |
| Bebbington, P | 1 |
| Remington, G | 2 |
| Hilger, E | 1 |
| Azorin, JM | 1 |
| Xiberas, X | 1 |
| Mallet, L | 1 |
| Artiges, E | 1 |
| Canal, M | 1 |
| Blin, O | 1 |
| Cesková, E | 1 |
| Drybcák, P | 1 |
| Hrobar, P | 1 |
| Lorenc, M | 1 |
| Spacek, J | 1 |
| Azorin, M | 1 |
| Bottai, T | 1 |
| Dalery, J | 1 |
| Garreau, G | 1 |
| Lisoprawski, A | 1 |
| Petitjean, F | 1 |
| Pedrosa Gil, F | 1 |
| Schneider, C | 1 |
| Rüther, E | 1 |
| Curran, MP | 2 |
| Perry, CM | 2 |
| Lewis, DA | 1 |
| Pitschel-Walz, G | 1 |
| Gessa, GL | 1 |
| Züchner, H | 1 |
| Yagdiran, O | 1 |
| Haasen, C | 1 |
| Nika, E | 1 |
| Krausz, M | 1 |
| Mota, NE | 1 |
| Lima, MS | 1 |
| Soares, BG | 1 |
| Green, B | 1 |
| Bottlender, R | 1 |
| Hofschuster, E | 1 |
| Dobmeier, P | 1 |
| Delcker, A | 1 |
| Schoon, ML | 1 |
| Oczkowski, B | 1 |
| Carnoy, P | 1 |
| Soubrie, P | 1 |
| Simon, P | 1 |
| Cassan, P | 1 |
| Cerisoli, M | 1 |
| Campanile, S | 1 |
| Campanile, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double-blind Controlled Trial to Assess the Benefits of Olanzapine and Amisulpride Combination Treatment in Acutely Ill Schizophrenia Patients. - COMBINE[NCT01609153] | Phase 4 | 328 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy[NCT03652974] | Phase 4 | 145 participants (Actual) | Interventional | 2018-09-06 | Completed | ||
| Bergen Psychosis Project 2 - The Bergen-Stavanger-Innsbruck-Trondheim Study[NCT01446328] | Phase 4 | 151 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)[NCT03543410] | Phase 2 | 344 participants (Actual) | Interventional | 2018-06-26 | Completed | ||
| Optimization of Treatment and Management of Schizophrenia in Europe[NCT01248195] | Phase 4 | 479 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS): the Effects of D2 Antagonism on Candidate Endophenotypes[NCT01154829] | 136 participants (Actual) | Interventional | 2008-12-31 | Completed | |||
| A Randomized, Double-blind, Comparison of the Efficacy and Safety of Olanzapine Versus Low-dose Olanzapine Plus Low-dose Trifluoperazine in the Treatment of Schizophrenia[NCT02704962] | Phase 4 | 94 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [NCT01615185] | Phase 4 | 96 participants (Actual) | Interventional | 2008-01-31 | Terminated | ||
| A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia[NCT02796859] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| An Open-Label Trial of Tocilizumab in Schizophrenia[NCT01696929] | Phase 1 | 8 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial[NCT05663749] | Phase 4 | 60 participants (Actual) | Interventional | 2022-09-20 | Completed | ||
| Comparison of Benzamide Derivates (Amisulpride, Moclobemide and Tiapride) as Treatment of Clozapine-induced Hypersalivation: Pilot Double Phase Study: Open and Double-blind[NCT00534573] | Phase 3 | 54 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Effectiveness of the RemedRugby Program, a Program of Ecological Cognitive Remediation of Social Cognition Disorders in Schizophrenia[NCT03775564] | 60 participants (Actual) | Interventional | 2014-11-30 | Completed | |||
| "Interventional Triple-negative Placebo-controlled Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia"[NCT06176456] | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | |||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical Global Impressions - Severity: Bipolar Version (CGI-BP-S) score (depression) is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill subjects. A higher score is associated with greater illness severity. (NCT03543410)
Timeframe: 6 Weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| SEP-4199 200 mg | -2.020 |
| SEP-4199 400 mg | -1.958 |
| Placebo | -1.739 |
MADRS is a clinician-rated assessment of the subject's level of depression. The measure contains 10 items that measure apparent and reported sadness, inner tension, reduced sleep and appetite, difficulty concentrating, lassitude, inability to feel, and pessimistic and suicidal thoughts, each ranging from 0 to 6. The MADRS total score ranges from 0 to 60, with higher scores indicating increased depressive symptoms (NCT03543410)
Timeframe: 6 Weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| SEP-4199 200 mg | -19.485 |
| SEP-4199 400 mg | -19.324 |
| Placebo | -16.196 |
The Brief Assessment of Cognition in Schizophrenia (BACS) is the metric used to characterize cognition in this study. The BACS consists of 6 subscales: Verbal Memory (range 0-75), Working Memory (range 0-28), Motor Speed (range 0-100), Verbal Fluency (measure is total number of words generated in two 60 second trials), Attention and Processing speed (range 0-110), and Executive Function (range 0-22). For each subscale, higher scores reflect better cognition. For each subscale, a Standard Deviation Score was calculated based on normative data (Keefe et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research 102 (2008) 108-115). The BACS composite score is calculated as the average Standard Deviation Score of the 6 subscale scores. The change in BACS composite score was calculated as the BACS composite score at 8 weeks minus the BACS composite score at baseline. (NCT01696929)
Timeframe: Change in BACS composite score from baseline to 8 weeks
| Intervention | Change in BACS Composite Score (Mean) |
|---|---|
| Tocilizumab | 0.7 |
The Positive and Negative Symptoms Scale (PANSS) is the metric used to characterize psychotic symptoms in this study. The PANSS consists of 30 items, each scored 1-7. The range for the PANSS total score is 30-210. There are 3 subscales - PANSS positive score (range 7-49), PANSS negative score (range 7-49), and PANSS general score (range 16-112). PANSS total score is the summation of these 3 subscales. Higher values for the total and subscale scores reflect more severe psychopathology. A positive change in PANSS total score reflects an increase in psychopathology. A negative change in PANSS total score reflects a decrease in psychopathology. (NCT01696929)
Timeframe: Change in PANSS total score from baseline to 8 weeks
| Intervention | Change in PANSS Total Score (Mean) |
|---|---|
| Tocilizumab | -2.6 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
59 reviews available for dan 2163 and Dementia Praecox
| Article | Year |
|---|---|
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Humans; Schizophrenia; Schizophrenia, Treatment-Resist | 2022 |
A systematic review and combined meta-analysis of concentration of oral amisulpride.
Topics: Aged; Amisulpride; Antipsychotic Agents; Drug Monitoring; Female; Humans; Schizophrenia; Sulpiride | 2020 |
The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis.
Topics: Amisulpride; Antipsychotic Agents; Cannabidiol; Double-Blind Method; Humans; Plant Oils; Randomized | 2020 |
Amisulpride - is it as all other medicines or is it different? An update.
Topics: Administration, Oral; Amisulpride; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, D | 2020 |
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Drug Resistan | 2017 |
Amisulpride Induced Oropharyngeal Dyskinesia in a patient with Schizophrenia: A case report and review of literature.
Topics: Adult; Amisulpride; Antipsychotic Agents; Humans; Male; Mouth; Pharynx; Schizophrenia; Stomatognathi | 2019 |
Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis.
Topics: Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; China; Cost-Benefit Analysis; Fem | 2018 |
Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Clozapine; Depression; Humans; Imidazoles; | 2019 |
Cannabis and schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cannabinoids; Humans; Marijuana Abuse; Medical M | 2014 |
Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Drug Monitoring; Female; Humans; Male; Ol | 2015 |
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clinical Trials | 2015 |
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
Topics: Administration, Oral; Amisulpride; Antipsychotic Agents; Benzodiazepines; Fluphenazine; Humans; Olan | 2016 |
Practical issues with amisulpride in the management of patients with schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Drug Resistance; Drug Therapy, Combination; Humans; Schizophrenia | 2008 |
Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring.
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Drug Monitoring | 2009 |
Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Drug Resistance; Drug Therapy, Com | 2009 |
Ziprasidone versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapin | 2009 |
Amisulpride versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Piperazines; Randomized Cont | 2010 |
Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride.
Topics: Activities of Daily Living; Amisulpride; Antipsychotic Agents; Clinical Trials as Topic; Humans; Qua | 2010 |
Olanzapine versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hum | 2010 |
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinic | 2010 |
Risperidone versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hum | 2011 |
Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia.
Topics: Amisulpride; Anhedonia; Antipsychotic Agents; Drug Resistance; Humans; Randomized Controlled Trials | 2012 |
Clinical implications of dopamine research in schizophrenia.
Topics: Amisulpride; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Receptors, Dopamine; Res | 2002 |
Amisulpride: progress and outcomes.
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Quality of Life; Receptors, Dopam | 2002 |
Switching to amisulpride.
Topics: Amisulpride; Antipsychotic Agents; Humans; Patient Care Planning; Practice Guidelines as Topic; Prac | 2002 |
Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.
Topics: Amisulpride; Animals; Antipsychotic Agents; Clinical Trials as Topic; Dopamine; Dose-Response Relati | 2002 |
Pharmacological approaches to the management of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzothiaze | 2003 |
Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
Topics: Adult; Amisulpride; Antipsychotic Agents; Body Weight; Clozapine; Dose-Response Relationship, Drug; | 2004 |
Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
Topics: Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dopamine Antagonists; Dopamine D2 | 2004 |
How do we choose between atypical antipsychotics? The advantages of amisulpride.
Topics: Adverse Drug Reaction Reporting Systems; Amisulpride; Antipsychotic Agents; Clinical Trials as Topic | 2004 |
[Current pharmacotherapy of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapin | 2004 |
[The features of atypical neuroleptic amisulpride action].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Clinical | 2004 |
Consensus on the use of substituted benzamides in psychiatric patients.
Topics: Amisulpride; Antipsychotic Agents; Benzamides; Depressive Disorder; Humans; Mental Disorders; Schizo | 2004 |
Amisulpride: a review of its use in the management of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug | 2004 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Cognitive Behavioral | 2003 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Haloperidol; Humans; | 2004 |
Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended.
Topics: Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Databases as Topic; Female; Human | 2005 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Chlorpromazine; Clozapine; Cognitive Behavioral Therapy; Dibenzot | 2005 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 2006 |
[The place of amisulpride in the atypical neuroleptic class].
Topics: Amisulpride; Animals; Depression; Humans; Limbic System; Neurologic Examination; Rats; Receptors, Do | 1996 |
Clinical update on amisulpride in deficit schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Depression; Dose-Response Relationship, Drug; Double-Blind | 1997 |
Amisulpride: from animal pharmacology to therapeutic action.
Topics: Amisulpride; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Humans; Limbic System; Mice; Ra | 1997 |
Safety of amisulpride (Solian): a review of 11 clinical studies.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Blood Cell Count | 1999 |
Amisulpride: a review of its efficacy in schizophrenia.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chronic Disease; C | 2000 |
Safety profile of amisulpride in short- and long-term use.
Topics: Amisulpride; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Drug Administration Sc | 2000 |
[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2000 |
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Costs; Human | 2000 |
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2001 |
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Topics: Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Controlled Clinical Trials as T | 2000 |
Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Psychiat | 2000 |
Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia.
Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Double-Blind Method; Feasibility Studies; France; Hu | 2001 |
Amisulpride: a review of its use in the management of schizophrenia.
Topics: Acute Disease; Administration, Oral; Adsorption; Amisulpride; Antipsychotic Agents; Chronic Disease; | 2001 |
Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Models, N | 2001 |
Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride.
Topics: Amisulpride; Antipsychotic Agents; Humans; Quality of Life; Schizophrenia; Schizophrenic Psychology; | 2002 |
Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
Topics: Amisulpride; Antipsychotic Agents; Humans; Psychiatric Status Rating Scales; Randomized Controlled T | 2002 |
Spotlight on amisulpride in schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Humans; Schizophrenia; Sulpiride | 2002 |
The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia.
Topics: Amisulpride; Antidepressive Agents; Benzamides; Dysthymic Disorder; Humans; Receptors, Dopamine D1; | 2002 |
Amisulpride for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Humans; Randomized Controlled Trials as Topic; Schizophrenia; Sul | 2002 |
Focus on amisulpride.
Topics: Amisulpride; Antipsychotic Agents; Controlled Clinical Trials as Topic; Dysthymic Disorder; Humans; | 2002 |
90 trials available for dan 2163 and Dementia Praecox
| Article | Year |
|---|---|
Changes of Mental State and Serum Prolactin Levels in Patients with Schizophrenia and Depression after Receiving the Combination Therapy of Amisulpride and Chloroprothixol Tablets.
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Chlo | 2022 |
Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
Topics: Adolescent; Adult; Aged; Amisulpride; Bayes Theorem; Double-Blind Method; Female; Humans; Male; Midd | 2022 |
Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial.
Topics: Adverse Childhood Experiences; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Hum | 2022 |
Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Humans; Olanzapine; Schizop | 2022 |
Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Cognition; Humans; Schizophrenia; Schizophrenia, Treat | 2022 |
Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Schizophrenia | 2023 |
Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Risperidone; Schizophrenia; Tre | 2023 |
A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design.
Topics: Acute Disease; Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Double-Blind Method; Drug | 2020 |
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Midd | 2020 |
Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders.
Topics: Adult; Amisulpride; Animals; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Dopamine | 2021 |
rs7968606 polymorphism of ANKS1B is associated with improvement in the PANSS general score of schizophrenia caused by amisulpride.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Carrier Proteins; Double-Blind Method; F | 2017 |
Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology.
Topics: Adult; Algorithms; Amisulpride; Antipsychotic Agents; Cognition Disorders; Electroencephalography; E | 2017 |
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clozapine; Cost-Benefit Analysis; Double-Blind Method; Dru | 2017 |
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Clozapine; Europe; Female; Humans; Male; Olanz | 2018 |
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.
Topics: Aged; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Double-Blind Method; Englan | 2018 |
Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort).
Topics: Adult; Age Factors; Amisulpride; Antipsychotic Agents; Cohort Studies; Europe; Female; Humans; Male; | 2019 |
Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Cost Savings; Diagnostic and Statistical Ma | 2013 |
Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Cost Savings; Diagnostic and Statistical Ma | 2013 |
Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Cost Savings; Diagnostic and Statistical Ma | 2013 |
Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Cost Savings; Diagnostic and Statistical Ma | 2013 |
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Hostilit | 2014 |
Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials.
Topics: Adult; Amisulpride; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Ma | 2014 |
Acute Effects of Haloperidol, Amisulpride, and Quetiapine on Bone Turnover Markers in Patients With Schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Biomarkers; Bone Remodeling; Bone Resorption; Female; Halo | 2015 |
The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Prospective | 2016 |
Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Comorbid | 2009 |
Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzamides; Corpus Striatum; Dose-Response Relationship, D | 2008 |
A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients.
Topics: Age Factors; Aged; Amisulpride; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Di | 2009 |
Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cognition Disorders; Female; Follow-Up Studies; Humans; Ma | 2009 |
Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cohort Studies; Female; Humans; Linear Models; Male; Progn | 2009 |
Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Drug Admi | 2010 |
Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; | 2010 |
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.
Topics: Adult; Amisulpride; Celecoxib; Cyclooxygenase 2 Inhibitors; Dopamine Antagonists; Dose-Response Rela | 2010 |
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.
Topics: Adult; Amisulpride; Celecoxib; Cyclooxygenase 2 Inhibitors; Dopamine Antagonists; Dose-Response Rela | 2010 |
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.
Topics: Adult; Amisulpride; Celecoxib; Cyclooxygenase 2 Inhibitors; Dopamine Antagonists; Dose-Response Rela | 2010 |
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.
Topics: Adult; Amisulpride; Celecoxib; Cyclooxygenase 2 Inhibitors; Dopamine Antagonists; Dose-Response Rela | 2010 |
Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation.
Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Clozapine; Cross-Over Studies; Female; Humans; Male; | 2011 |
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Haloperid | 2011 |
The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Male; Prospective Studi | 2011 |
Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Drug Tolerance; Female; Humans; Hyperprolactinemia; Male; | 2012 |
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dibenzot | 2013 |
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
Topics: Acute Disease; Adult; Amides; Amisulpride; Antipsychotic Agents; Arachidonic Acids; Cannabidiol; Dou | 2012 |
A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.
Topics: Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Disea | 2012 |
Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms.
Topics: Amisulpride; Antipsychotic Agents; Double-Blind Method; Female; Humans; Intention; Male; Psychiatric | 2013 |
Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis.
Topics: Adolescent; Adult; Affect; Aged; Amisulpride; Antipsychotic Agents; Double-Blind Method; Factor Anal | 2002 |
Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels.
Topics: Adult; Amisulpride; Antipsychotic Agents; Drug Administration Schedule; Female; Flupenthixol; Humans | 2002 |
A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; B | 2002 |
Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Halo | 2002 |
Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Chi-Square Distribution; Chronic Disease | 2002 |
Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.
Topics: Amisulpride; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Pilot Projects; Psychi | 2003 |
Plasma amisulpride levels in schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Age Factors; Amisulpride; Antipsychotic Agents; Biomimetics; Chromatography, High | 2004 |
A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brief Ps | 2004 |
Clozapine with amisulpride for refractory schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Drug Therapy, C | 2004 |
Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine.
Topics: Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Diagnostic and Statist | 2004 |
Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Attention; Benzodiazepines; Cognition; D | 2005 |
Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzamides; Binding, Competitive; Brain Mapping; Case-Cont | 2005 |
Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cost of Illness; Cost-Benefit Analysis; Costs and Cost Ana | 2005 |
The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Sche | 2005 |
Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine.
Topics: Acoustic Stimulation; Adult; Amisulpride; Antipsychotic Agents; Attention; Benzodiazepines; Dopamine | 2006 |
Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Cross-Over Studies; Double-Blind Method; Female; Human | 2006 |
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Amisulpride; Antipsychotic Agents; Behavioral Sympto | 2006 |
Switching to amisulpride monotherapy for treatment-resistant schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Drug Resistance; Follow-Up Studies; Humans; Male; Psychiat | 2006 |
Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Drug Administration Schedule; Drug Monitoring; Drug Tolera | 2006 |
Early changes of plasma lipids during treatment with atypical antipsychotics.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; B | 2006 |
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
Topics: Adult; Affect; Amisulpride; Antipsychotic Agents; Attention; Basal Ganglia Diseases; Benzodiazepines | 2006 |
A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression.
Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depres | 2006 |
Delta power in sleep in relation to neuropsychological performance in healthy subjects and schizophrenia patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Case-Control Studies; Delta Rhythm; Female; Fourier Analys | 2006 |
Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Female; Humans; International Classification of Diseases; | 2007 |
A preliminary fMRI study of the effects on cortical activation of the treatment of refractory auditory hallucinations with rTMS.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clozapine; Combined Modality Therapy; Female; Functional L | 2007 |
Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weig | 2007 |
Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dose- | 2007 |
Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Depressive Disorder; Electrocardiography; Endp | 2007 |
Increase in plasma concentration of amisulpride after addition of concomitant lithium.
Topics: Adult; Amisulpride; Antimanic Agents; Antipsychotic Agents; Borderline Personality Disorder; Chromat | 2007 |
Two-year study of relapse prevention by a new education program in schizophrenic patients treated with the same antipsychotic drug.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clinical Trials, Phase IV as Topic; Control Groups; Female | 2008 |
Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Combined Modality Therapy; Drug Administration | 2007 |
Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibe | 2007 |
Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapin | 2008 |
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; H | 2008 |
Amisulpride--an open clinical study of a new benzamide in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Electroe | 1984 |
Improvement of some schizophrenic deficit symptoms with low doses of amisulpride.
Topics: Adult; Amisulpride; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Sched | 1995 |
Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Apomorphine; Dopamine Agonists; Ergolines; Female; Growth | 1993 |
Treatment of negative symptoms in schizophrenia with amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Depression; Dose-Response Relationship, Drug; Double-Blind | 1995 |
Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine.
Topics: Adult; Amisulpride; Antipsychotic Agents; Arousal; Attention; Brain Mapping; Cerebral Cortex; Dose-R | 1994 |
In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.
Topics: Adult; Amisulpride; Brain; Female; Humans; Male; Receptors, Dopamine D2; Schizophrenia; Sulpiride; T | 1996 |
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Amisulpride; Antiparkinson Agents; Antipsychotic Agents; Double-Blin | 1997 |
Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group.
Topics: Adult; Akathisia, Drug-Induced; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; D | 1997 |
One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol.
Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Humans | 1997 |
Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Bl | 1998 |
Neuroendocrine response to antipsychotics: effects of drug type and gender.
Topics: Adult; Amisulpride; Antipsychotic Agents; Double-Blind Method; Female; Flupenthixol; Human Growth Ho | 1999 |
Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind | 1999 |
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Body Weight; Double-Blind Method; Female; H | 1999 |
Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induce | 2000 |
Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Double-Blind M | 2000 |
Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; | 2001 |
Treatment of positive and negative symptoms: pharmacologic approaches.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug | 1990 |
Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Halop | 1990 |
[Benzamides, a therapeutic response adapted to 2 sides, paranoid and hebephrenic, of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Benzamides; Clinical Trials as Topic; Double-Blind Method; Humans | 1985 |
172 other studies available for dan 2163 and Dementia Praecox
| Article | Year |
|---|---|
Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level.
Topics: Adolescent; Adult; Age Factors; Amisulpride; Antipsychotic Agents; Asian People; Computer Simulation | 2021 |
Analysis of Gut Microbiota in Patients with Exacerbated Symptoms of Schizophrenia following Therapy with Amisulpride: A Pilot Study.
Topics: Amisulpride; Gastrointestinal Microbiome; Humans; Pilot Projects; RNA, Ribosomal, 16S; Schizophrenia | 2022 |
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Cl | 2022 |
Amisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring data.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Creatine Kinase; Drug Monitoring; Hormones; Humans; Is | 2022 |
Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders.
Topics: Amisulpride; Antipsychotic Agents; Humans; Quality of Life; Schizophrenia; Treatment Outcome | 2023 |
Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders.
Topics: Amisulpride; Antipsychotic Agents; Humans; Quality of Life; Schizophrenia; Treatment Outcome | 2023 |
Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders.
Topics: Amisulpride; Antipsychotic Agents; Humans; Quality of Life; Schizophrenia; Treatment Outcome | 2023 |
Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders.
Topics: Amisulpride; Antipsychotic Agents; Humans; Quality of Life; Schizophrenia; Treatment Outcome | 2023 |
Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Hedgehog Proteins; Male; Rats; Rats, Wista | 2023 |
Age, Sex, and Comedication Effects on the Steady-State Plasma Concentrations of Amisulpride in Chinese Patients with Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; East Asian People; Female; Humans; Male; Retrospective Studies; S | 2023 |
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Humans; Hyperprol | 2023 |
[Amisulpride, a one-of-a-kind and highly efficacious antipsychotic agent in the treatment of first-episode psychosis].
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Drug Monitoring; Drug Substitution; Humans; Olanzapine | 2019 |
Treatment of First-Episode Schizophrenia in a Young Woman.
Topics: Amisulpride; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; | 2020 |
A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort).
Topics: Adult; Alleles; Amisulpride; Antipsychotic Agents; Cohort Studies; Female; Genetic Loci; Genome-Wide | 2020 |
Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China.
Topics: Amisulpride; Antipsychotic Agents; China; Cost-Benefit Analysis; Decision Support Techniques; Humans | 2020 |
Effects of Atypical Antipsychotics on Neuroactive Vitamins in Patients With Schizophrenia.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Case-Control Studies; Female; Hu | 2020 |
Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia - data from the OPTiMiSE trial.
Topics: Adult; Amisulpride; Antipsychotic Agents; Behavioral Symptoms; Female; Humans; Male; Middle Aged; Ps | 2020 |
Severe clozapine-induced agranulocytosis: successful treatment with G-CSF and rechallenge of clozapine plus D2 potentiation therapy (amisulpride).
Topics: Agranulocytosis; Amisulpride; Antipsychotic Agents; Clozapine; Granulocyte Colony-Stimulating Factor | 2020 |
Identification and Quantification of Antipsychotics in Blood Samples by LC-MS-MS: Case Reports and Data from Three Years of Routine Analysis.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chromatography, Liquid; Clo | 2020 |
Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study.
Topics: Amisulpride; Antipsychotic Agents; Case-Control Studies; Depression; Humans; Psychiatric Status Rati | 2020 |
What is the "best intro"-explanatory versus pragmatic antipsychotic drug trials.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Schizophrenia | 2020 |
Prediction of Self-Report Cognitive Function for the Symptomatic Remission in Schizophrenia Treated with Amisulpride: a Multicenter, 8-Week Case-Control Study.
Topics: Amisulpride; Antipsychotic Agents; Case-Control Studies; Cognition; Humans; Psychiatric Status Ratin | 2021 |
Pragmatic antipsychotics trial-caution in interpretation.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Schizophrenia | 2021 |
Pragmatic antipsychotics trial-caution in interpretation - Authors' reply.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Schizophrenia | 2021 |
Occurrence of macroprolactinemia in schizophrenia patients treated with risperidone or amisulpride.
Topics: Amisulpride; Antipsychotic Agents; Humans; Hyperprolactinemia; Prolactin; Risperidone; Schizophrenia | 2022 |
Study on the relationship among dose, concentration and clinical response in Chinese schizophrenic patients treated with Amisulpride.
Topics: Amisulpride; Antipsychotic Agents; China; Female; Humans; Male; Psychiatric Status Rating Scales; Sc | 2021 |
Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Female; Humans; Male; | 2018 |
Polymorphism of the SNAP25 gene is associated with symptom improvement in schizophrenic patients treated with amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Female; Genotype; Humans; Male; Middle Aged; Polymorphism, | 2017 |
Restless Legs Syndrome and Schizophrenia: A Case Report.
Topics: Adult; Amisulpride; Antipsychotic Agents; Female; Humans; Restless Legs Syndrome; Schizophrenia | 2018 |
Response of Catatonia to Amisulpride and Lorazepam in an Adolescent with Schizophenia.
Topics: Adolescent; Amisulpride; Anti-Anxiety Agents; Antipsychotic Agents; Catatonia; Humans; Lorazepam; Ma | 2018 |
[Aripiprazole for drug-induced sexual dysfunction in schizophrenic males].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Male; Prolact | 2017 |
Rapid remission of first-episode schizophrenia with standardised treatment.
Topics: Amisulpride; Clozapine; Humans; Olanzapine; Psychotic Disorders; Schizophrenia | 2018 |
White matter integrity associated with severity reductions in positive symptoms after amisulpride treatment in drug-free patients with schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Diffusion Tensor Imaging; Female; Humans; Image Processing | 2018 |
Antipsychotic treatments: who is really failing here? - Authors' reply.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Humans; Olanzapine; Psychotic Disorders; Schizophrenia | 2018 |
Antipsychotic treatments: who is really failing here?
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Humans; Olanzapine; Psychotic Disorders; Schizophrenia | 2018 |
The relation between dopamine D
Topics: Adult; Amisulpride; Case-Control Studies; Corpus Striatum; Denmark; Dopamine D2 Receptor Antagonists | 2020 |
Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D
Topics: Adult; Amisulpride; Antipsychotic Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Fe | 2019 |
Amisulpride-associated acute onset of metabolic syndrome in a schizophrenia patient.
Topics: Adult; Amisulpride; Antipsychotic Agents; Female; Humans; Metabolic Syndrome; Schizophrenia; Sulpiri | 2013 |
Safety of the electroconvulsive therapy and amisulpride combination.
Topics: Adult; Amisulpride; Antipsychotic Agents; Case-Control Studies; Combined Modality Therapy; Electroco | 2013 |
[Clinical and experimental research of immunomodulatory effect of amisulpride].
Topics: Adult; Amisulpride; Animals; Antibodies, Anti-Idiotypic; Antipsychotic Agents; Disease Models, Anima | 2012 |
Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats.
Topics: Amisulpride; Animals; Ketamine; Male; Phenols; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Sch | 2013 |
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cabergoline; Diagnostic and Statistical Manual of Mental D | 2013 |
[Effect of antipsychotic amisulpride on immune reactivity].
Topics: Amisulpride; Animals; Antigens, CD; Antipsychotic Agents; Humans; Immune Tolerance; Male; Mice; Mice | 2013 |
Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Fem | 2014 |
Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital.
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Blood Glucose; Body Mass Index; Cholesterol; C | 2014 |
Case report of a patient presenting both schizophrenia and Charcot-Marie-Tooth disease.
Topics: Adult; Amisulpride; Antipsychotic Agents; Charcot-Marie-Tooth Disease; Humans; Male; Schizophrenia; | 2013 |
Detecting potential adverse reactions of sulpiride in schizophrenic patients by prescription sequence symmetry analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Child; Cohort Studies | 2014 |
Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients.
Topics: Acoustic Stimulation; Adult; Amisulpride; Analysis of Variance; Case-Control Studies; Dopamine Antag | 2014 |
Persistent hiccups associated with switching from paliperidone to amisulpride.
Topics: Amisulpride; Antipsychotic Agents; Drug Substitution; Hiccup; Humans; Male; Paliperidone Palmitate; | 2015 |
Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Mapping; Clozapine; E | 2015 |
Amisulpride for older patients with long-standing schizophrenia.
Topics: Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Cohort Studies; Female; Humans; Male; Mi | 2014 |
Clozapine augmentation with amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clozapine; Drug Synergism; Humans; Male; Schizophrenia; Su | 2014 |
Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy.
Topics: Administration, Oral; Adult; Aged; Amisulpride; Antipsychotic Agents; Drug Therapy, Combination; Fem | 2015 |
Amisulpride-associated mania in a young adult with schizophrenia and cerebral disease.
Topics: Amisulpride; Antipsychotic Agents; Bipolar Disorder; Cerebral Palsy; Drug Administration Schedule; H | 2014 |
Accounting for uncertainty due to 'last observation carried forward' outcome imputation in a meta-analysis model.
Topics: Amisulpride; Antipsychotic Agents; Bayes Theorem; Bias; Biostatistics; Humans; Markov Chains; Meta-A | 2015 |
DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; DNA; Dopamine Antagonists; Female; Genot | 2015 |
Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.
Topics: Adolescent; Adult; Amisulpride; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Female; Huma | 2015 |
Improvement of ketamine-induced social withdrawal in rats: the role of 5-HT7 receptors.
Topics: Amisulpride; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Excitatory Ami | 2015 |
Reversible Amisulpride-induced Elevation of Creatine Kinase (CK): A Case Series from the German AMSP Pharmacovigilance Project.
Topics: Adult; Amisulpride; Antipsychotic Agents; Creatine Kinase; Female; Humans; Male; Middle Aged; Myalgi | 2015 |
Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Prescriptions; Drug Thera | 2015 |
Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Brain; Dopamine D2 Receptor Antagonists; Elect | 2015 |
Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia.
Topics: Amisulpride; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Body Temperature Regulatio | 2015 |
Treatment-Resistant Schizophrenia in a Patient With 17q12 Duplication.
Topics: Amisulpride; Antipsychotic Agents; Chromosomes, Human, Pair 17; Drug Resistance; Humans; Male; Mosai | 2016 |
Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
Topics: Acute Disease; Adult; Amisulpride; Anisotropy; Antipsychotic Agents; Brain; Diffusion Magnetic Reson | 2016 |
Severe acute pancreatitis, neuroleptic malignant syndrome and grand mal seizures associated with elevated amisulpride and low clozapine serum levels.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Humans; Male; Middle Aged; Neuroleptic Malignant Syndr | 2015 |
Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment.
Topics: Adult; Amisulpride; Antipsychotic Agents; Case-Control Studies; Catechol O-Methyltransferase; Female | 2016 |
Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment.
Topics: Adolescent; Adult; Amisulpride; Anticipation, Psychological; Antipsychotic Agents; Dopamine D2 Recep | 2016 |
[Aripiprazole, gambling disorder and compulsive sexuality].
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Compulsive Behavior; Gambling; Humans; Male; | 2016 |
Adjunctive ondansetron in schizophrenia--A pilot study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Feasibility Studies; | 2016 |
Use of amisulpride in treating adolescent onset schizophrenia associated with stuttering priapism induced by multiple antipsychotics.
Topics: Adolescent; Amisulpride; Antipsychotic Agents; Humans; Male; Priapism; Schizophrenia; Sulpiride; Tre | 2016 |
Antipsychotic Drugs Differentially Affect mRNA Expression of Genes Encoding the Neuregulin 1-Downstream ErbB4-PI3K Pathway.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cell Line, Tumor; Cell Survival; Clozapine; Gene | 2016 |
Asymptomatic bradycardia and hypotension associated with amisulpride: A case report.
Topics: Adult; Amisulpride; Antipsychotic Agents; Bradycardia; Female; Humans; Hypotension; Schizophrenia; S | 2016 |
Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Female; Humans; Mal | 2017 |
Fatality due to amisulpride toxicity: a case report.
Topics: Adult; Amisulpride; Antipsychotic Agents; Forensic Toxicology; Humans; Male; Schizophrenia; Sulpirid | 2008 |
Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brain; Female; Humans; Hyperprolactinemia; Magnetic Resona | 2009 |
Repeated acute dystonia following administration of amisulpride and ziprasidone in a patient with iron deficiency.
Topics: Adolescent; Amisulpride; Anemia, Iron-Deficiency; Antipsychotic Agents; Dibenzothiazepines; Dystonia | 2008 |
Amisulpride-induced both oculogyric crisis and trismus.
Topics: Amisulpride; Antipsychotic Agents; Dystonia; Humans; Male; Ocular Motility Disorders; Schizophrenia; | 2008 |
Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine. 3-month follow-up.
Topics: Amisulpride; Antipsychotic Agents; Autonomic Nervous System; Benzodiazepines; Female; Heart Rate; Hu | 2008 |
A flow-cytometric method to investigate glutamate-receptor-sensitivity in whole blood platelets - results from healthy controls and patients with schizophrenia.
Topics: Adult; Amisulpride; Analysis of Variance; Blood Platelets; Calcium; Dizocilpine Maleate; Dopamine An | 2009 |
Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis.
Topics: Age of Onset; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Dyskinesia, Drug-Induced; | 2009 |
[Costs of treatment in patients with schizophrenia switched to amisulpride--one-year follow-up].
Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Cost of Illness; Drug Costs; Efficiency; Employment; | 2008 |
Successful treatment with amisulpride for the progression of olfactory reference syndrome to schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Humans; Male; Middle Aged; Olfactory Perception; Perceptual Disor | 2009 |
Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Diagnosis, Differential; Female; Humans; Hyper | 2009 |
Amisulpride treatment of adolescent patients with schizophrenia or schizo-affective disorders.
Topics: Adolescent; Amisulpride; Antiparkinson Agents; Antipsychotic Agents; Biperiden; Dose-Response Relati | 2009 |
[Prolonged QT interval in two cases of amisulpride overdose].
Topics: Amisulpride; Antipsychotic Agents; Drug Overdose; Female; Follow-Up Studies; Humans; Long QT Syndrom | 2010 |
Targeting cognition in schizophrenia research: from etiology to treatment.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Dibenzothiazepin | 2009 |
Causal model of insight and psychopathology based on the PANSS factors: 1-year cross-sectional and longitudinal revalidation.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cognition; Female; Humans; Male; Models, Psychological; Ps | 2009 |
The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Anxiety; Benzodiazepines; Cognition Disorders; Depressive | 2010 |
Familial differential treatment response in schizophrenia--lessons from a case of three affected siblings.
Topics: Adult; Amisulpride; Antipsychotic Agents; Dibenzothiazepines; Diseases in Twins; Female; Humans; Lor | 2010 |
Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Case-C | 2010 |
Amisulpride-induced tardive dyskinesia in childhood onset schizophrenia.
Topics: Adolescent; Amisulpride; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Schizophrenia | 2010 |
Tardive dystonia induced by switch of atypical antipsychotics.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Female; Hum | 2010 |
Amisulpride monotherapy in a patient with clozapine-resistant schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Hu | 2010 |
Amisulpride overdose: suggested management of prolonged QTc.
Topics: Adult; Amisulpride; Antipsychotic Agents; Calcium; Drug Overdose; Humans; Hypocalcemia; Infusions, I | 2010 |
Amisulpride may worsen dyskinesia and trigger new-onset dyskinetic movements.
Topics: Aged; Amisulpride; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Schizophrenia; Su | 2010 |
Pisa syndrome during amisulpride treatment.
Topics: Adult; Amisulpride; Antipsychotic Agents; Dystonia; Humans; Male; Schizophrenia; Sulpiride | 2010 |
Estimation of rac-amisulpride transfer into milk and of infant dose via milk during its use in a lactating woman with bipolar disorder and schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Bipolar Disorder; Breast Feeding; Child Development; Chrom | 2011 |
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
Topics: Adult; Age Factors; Alleles; Amisulpride; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodi | 2011 |
The effectiveness of the combination therapy of amisulpride and quetiapine for managing treatment-resistant schizophrenia: a naturalistic study.
Topics: Adult; Amisulpride; Dibenzothiazepines; Disease Management; Drug Therapy, Combination; Female; Human | 2011 |
Beta-glucan from Saccharomyces cerevisiae reduces plasma lipid peroxidation induced by haloperidol.
Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; beta-Glucans; Female; Haloperidol; H | 2011 |
Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Fem | 2011 |
Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Diagn | 2011 |
Secondary pseudomyopia induced by amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Diagnosis, Differential; Female; Humans; Myopia; Refractio | 2011 |
Amisulpride augmentation of clozapine in refractory schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Drug Synergism; Humans; Male; Middle Aged; Schizophren | 2011 |
Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.
Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; Attention; Benzodiazepines; Dibenzot | 2012 |
Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Clozapine; Cohort S | 2013 |
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Estradiol; Follicle Stimula | 2012 |
Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Interpretation, Statistical; | 2012 |
Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Europe; Female; Human | 2012 |
Risperidone augmentation with amisulpride: the blue-tongue sign.
Topics: Amisulpride; Dopamine Antagonists; Drug Therapy, Combination; Humans; Male; Melanins; Pigmentation; | 2012 |
Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Female; Humans; Mal | 2013 |
Attaining and sustaining remission of predominant negative symptoms.
Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Double-Blin | 2013 |
Improvements in micturition and urinary retention after switching from amisulpiride to paliperidone in a schizophrenic patient.
Topics: Amisulpride; Antipsychotic Agents; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Py | 2012 |
Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Depression; Double-Blind M | 2002 |
Switching antipsychotic medications: general recommendations and switching to amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Female; Humans; Male; Retrospective Studies; Schizophrenia | 2002 |
Catatonia and transcranial magnetic stimulation.
Topics: Adolescent; Amisulpride; Antipsychotic Agents; Catatonia; Female; Humans; Prefrontal Cortex; Schizop | 2002 |
Amisulpride-induced mania in a patient with schizophrenia.
Topics: Adolescent; Amisulpride; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Schizophrenia; Sulp | 2003 |
Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzamides; Corpus Striatum; Dopamine D2 Receptor Antagoni | 2003 |
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze | 2003 |
Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Drug Therapy, Combinatio | 2004 |
Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study.
Topics: Adult; Amisulpride; Chi-Square Distribution; Drug Utilization Review; Female; Hospitalization; Human | 2004 |
Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brain; Contrast Media; Dopamine D2 Receptor Antagonists; D | 2004 |
Amisulpride-associated pedal edema.
Topics: Amisulpride; Antipsychotic Agents; Diuretics; Edema; Foot Diseases; Furosemide; Humans; Male; Middle | 2004 |
EEG abnormalities under treatment with atypical antipsychotics: effects of olanzapine and amisulpride as compared to haloperidol.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dose-Response Re | 2004 |
[Rehospitalization rates of newly diagnosed schizophrenic patients on atypical neuroleptic medication].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Benzodiazepines; Fema | 2004 |
Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome.
Topics: Adult; Amisulpride; Antipsychotic Agents; Coma; Creatine Kinase; Female; Humans; Leukocytosis; Neuro | 2004 |
Effectiveness of amisulpride augmentation of clozapine in a non-responder to either drug alone: a case report.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Drug Synergism; D | 2005 |
High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.
Topics: Adult; Algorithms; Amisulpride; Antipsychotic Agents; Area Under Curve; Caudate Nucleus; Cerebral Co | 2004 |
Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clozapine; Drug Synergism; Drug Therapy, Combination; Huma | 2005 |
Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administ | 2004 |
[Costs related to change to amisulpride in patients suffering from schizophrenia].
Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Cost of Illness; Cost Savings; Cost-Benefit Analysis | 2004 |
[Functional magnetic resonance tomography of central motor areas in schizophrenic patients].
Topics: Amisulpride; Antipsychotic Agents; Biomechanical Phenomena; Dyskinesia, Drug-Induced; Gait Apraxia; | 2005 |
D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brain; Dose-Response Relationship, Drug; Female; Humans; I | 2005 |
Amisulpride and cardiomyopathy.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cardiomyopathies; Humans; Hypertrophy, Left Ventricular; M | 2005 |
Clinical implications of Brief Psychiatric Rating Scale scores.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olan | 2005 |
Amisulpride related tic-like symptoms in an adolescent schizophrenic.
Topics: Adolescent; Amisulpride; Antipsychotic Agents; Female; Humans; Schizophrenia; Sulpiride; Tic Disorde | 2006 |
Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Dose-Response Relatio | 2007 |
Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Outpa | 2006 |
Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient.
Topics: Adult; Amisulpride; Antipsychotic Agents; Female; Humans; Schizophrenia; Sulpiride; Time Factors; We | 2006 |
Is the superior efficacy of new generation antipsychotics an artifact of LOCF?
Topics: Amisulpride; Artifacts; Benzodiazepines; Bias; Flupenthixol; Haloperidol; Humans; Olanzapine; Patien | 2007 |
Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Drug Thera | 2007 |
Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Body Mass Index; Clozapine; Female; Gluc | 2007 |
[Endocrine side effects among psychiatric patients treated with antipsychotics].
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Breast; Dibenzothiazepines; | 2006 |
Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.
Topics: Adult; Ambulatory Care; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cohort Studie | 2006 |
Atypical antipsychotics and pituitary neoplasms in the WHO database.
Topics: Adenoma; Adult; Adverse Drug Reaction Reporting Systems; Amisulpride; Antipsychotic Agents; Causalit | 2007 |
Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Female; Humans; | 2007 |
Amenorrhea after sertraline introduction in an amisulpride-treated patient with undiagnosed polycystic ovary disease.
Topics: Adult; Amenorrhea; Amisulpride; Antipsychotic Agents; Depression; Drug Interactions; Female; Humans; | 2007 |
Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Drug Utilization; Dyskinesia, | 2007 |
Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; China; Cost of Illness; Cost-Benefit Anal | 2007 |
Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Bipolar Disorder; Cohort Studies; Cross-Sectional Studies; | 2007 |
Clozapine and amisulpride in refractory schizophrenia and alcohol dependence.
Topics: Alcoholism; Amisulpride; Antipsychotic Agents; Behavior, Addictive; Blood Glucose; Clozapine; Comorb | 2007 |
Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Humans; Male; Middle Aged; Myocard | 2008 |
Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study.
Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Dibenz | 2008 |
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Comorbidity; Dopamine Antagonists; Dose-Resp | 2008 |
Amisulpride-induced dystonia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Dystonia; Female; Humans; Schizophrenia; Sulpiride | 2008 |
Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients.
Topics: Adolescent; Adult; Amisulpride; Animals; Antipsychotic Agents; Cerebral Cortex; Chlorpromazine; Cloz | 1998 |
Amisulpride in schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Humans; Schizophrenia; Sulpiride | 1998 |
[Amisulpride--a neuroleptic agent for all phases of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Chronic Disease; Humans; Hyperkinesis; Hypertension; Risk Factors | 1999 |
Amisulpride: its role in the therapeutic management of the schizophrenic patient. Introduction.
Topics: Amisulpride; Antipsychotic Agents; Cognition Disorders; Humans; Schizophrenia; Sulpiride | 2000 |
Amisulpride: its role in the therapeutic management of the schizophrenia patient. Conclusions.
Topics: Amisulpride; Antipsychotic Agents; Humans; Schizophrenia; Sulpiride | 2000 |
[Atypical antipsychotics].
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; | 2000 |
From pharmacological profiles to clinical outcomes.
Topics: Amisulpride; Antipsychotic Agents; Frontal Lobe; Humans; Limbic System; Receptors, Dopamine; Schizop | 2000 |
Is amisulpride an 'atypical' atypical antipsychotic agent?
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Limbic System; Receptors, Dopamin | 2000 |
Acute phase of schizophrenia: impact of atypical antipsychotics.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Haloperidol; Humans; Prognosis; Recurrence; Risper | 2000 |
In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Recepto | 2001 |
The changes of biological markers and treatment efficacy in schizophrenia.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Biomarkers; Brain; Cognition; Dexamethasone | 2001 |
[Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Creatine Kinase; Drug Interactions; Genet | 2001 |
Atypical antipsychotic medications and the treatment of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Double-Blind Method; Humans; Meta-Analysis as Topic; Psychiatric | 2002 |
[QT prolongation and torsade de pointes--tachycardia in therapy with maprotiline].
Topics: Amisulpride; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Brain Damage, Chronic; | 2002 |
Switching to amisulpride due to hepatic complications.
Topics: Adult; Amisulpride; Antipsychotic Agents; Chemical and Drug Induced Liver Injury; Flupenthixol; Halo | 2002 |
[Atypical neuroleptics--a heterogenous group. Valuable option in acute psychoses].
Topics: Amisulpride; Antipsychotic Agents; Germany; Humans; Meta-Analysis as Topic; Randomized Controlled Tr | 2002 |
Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.
Topics: Amisulpride; Antipsychotic Agents; Clozapine; Female; Humans; Middle Aged; Neuroleptic Malignant Syn | 2002 |
Performance deficit induced by low doses of dopamine agonists in rats. Toward a model for approaching the neurobiology of negative schizophrenic symptomatology?
Topics: Amisulpride; Animals; Antipsychotic Agents; Apomorphine; Disease Models, Animal; Male; Phenothiazine | 1986 |
[Efficacy of low doses of atypical neuroleptics (benzamides) in defect states].
Topics: Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Humans; Schizophrenia; Sulpiride | 1986 |
Pisa syndrome. Report of a case.
Topics: Adult; Amisulpride; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans; Male; Schiz | 1988 |